Document: SEC Filing

Company: Johnson & Johnson
Ticker: JNJ
CIK: 200406
Form Type: 10-Q
Filing Date: 2025-07-24
Accession Number: 0000200406-25-000178
Source: 10-Q_2025-07-24_0000200406-25-000178.txt

---

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM
10-Q

☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

for the quarterly period ended
June 29, 2025

or
☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from            to

Commission file number
1-3215

Johnson & Johnson
(Exact name of registrant as specified in its charter)
New Jersey 22-1024240
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

One Johnson & Johnson Plaza

New Brunswick
,
New Jersey

08933

(Address of principal executive offices)
Registrant’s telephone number, including area code (
732
) 
524-0400

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements                     for the past 90 days.
☑

Yes

☐
No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
☑

Yes

☐
No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☑ Accelerated filer ☐
Non-accelerated filer ☐ Smaller reporting company ☐
Emerging growth company ☐

If an emerging growth company, indicated by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
☐
Yes
☑
No
SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT
Title of each class Trading Symbol Name of each exchange on which registered
Common Stock, Par Value $1.00 JNJ New York Stock Exchange
1.150% Notes Due November 2028 JNJ28 New York Stock Exchange
2.700% Notes Due February 2029 JNJ29B New York Stock Exchange
3.200% Notes Due June 2032 JNJ32 New York Stock Exchange
3.050% Notes Due February 2033 JNJ33B New York Stock Exchange
1.650% Notes Due May 2035 JNJ35 New York Stock Exchange
3.350% Notes Due June 2036 JNJ36A New York Stock Exchange
3.350% Notes Due February 2037 JNJ37B New York Stock Exchange
3.550% Notes Due June 2044 JNJ44 New York Stock Exchange
3.600% Notes Due February 2045 JNJ45 New York Stock Exchange
3.700% Notes Due February 2055 JNJ55 New York Stock Exchange

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
On July 18, 2025,
2,408,338,872
shares of Common Stock, $1.00 par value, were outstanding.
JOHNSON & JOHNSON AND SUBSIDIARIES
Table of contents
Item Page
Part I
Financial information 1
Item 1 Financial statements (unaudited) 1
Consolidated balance sheets — June 29, 2025 and December 29, 2024 1
Consolidated statements of earnings for the fiscal second quarters ended June 29 , 2025 and June 3 0 , 2024 2
Consolidated statements of earnings for the fiscal six months ended June 29 , 2025 and June 3 0 , 2024 3
Consolidated statements of comprehensive income for the fiscal second quarters and fiscal six months ended June 29 , 2025 and June 3 0 , 2024 4
Consolidated statements of equity for the fiscal second quarters and fiscal six months ended June 29 , 2025 and June 3 0 , 2024 5
Consolidated statements of cash flows for the fiscal six months ended June 29 , 2025 and June 3 0 , 2024 7
Notes to consolidated financial statements 8
Item 2 Management’s discussion and analysis of financial condition and results of operations 41
Item 3 Quantitative and qualitative disclosures about market risk 57
Item 4 Controls and procedures 57
Part II
Other information 59
Item 1 Legal proceedings 59
Item 2 Unregistered sales of equity securities and use of proceeds 59
Item 5 Other information 60
Item 6 Exhibits 60
Signatures 61

Cautionary note regarding forward-looking statements
This Quarterly Report on Form 10-Q and Johnson & Johnson’s other publicly available documents contain “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Management and representatives of Johnson & Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and reflect management’s assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and other words of similar meaning in conjunction with, among other things: discussions of future operations, expected operating results, financial performance; impact of planned acquisitions and dispositions; impact and timing of restructuring initiatives including associated cost savings and other benefits; the Company’s strategy for growth; product development activities; regulatory approvals; market position and expenditures.
Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of the Company’s control. Investors should realize that if underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, the Company’s actual results and financial condition could vary materially from expectations and projections expressed or implied in its forward-looking statements. Investors are therefore cautioned not to rely on these forward-looking statements. Risks and uncertainties include, but are not limited to:
Risks related to product development, market success and competition
•
Challenges and uncertainties inherent in innovation and development of new and improved products and technologies on which the Company’s continued growth and success depend, including uncertainty of clinical outcomes, additional analysis of existing clinical data, obtaining regulatory approvals, health plan coverage and customer access, and initial and continued commercial success;
•
Challenges to the Company’s ability to secure and maintain adequate patent and other intellectual property rights for new and existing products and technologies in the United States and other important markets;
•
The impact of patent expirations, typically followed by the introduction of competing generic, biosimilar or other products and resulting revenue and market share losses;
•
Increasingly aggressive and frequent challenges to the Company’s patents by competitors and others seeking to launch competing generic, biosimilar or other products and increased receptivity of courts, the United States Patent and Trademark Office and other decision makers to such challenges, potentially resulting in loss of market exclusivity and rapid decline in sales for the relevant product sooner than expected;
•
Competition in research and development of new and improved products, processes and technologies, which can result in product and process obsolescence;
•
Competition to reach agreement with third parties for collaboration, licensing, development and marketing agreements for products and technologies;
•
Competition based on cost-effectiveness, product performance, technological advances and patents attained by competitors; and
•
Allegations that the Company’s products infringe the patents and other intellectual property rights of third parties, which could adversely affect the Company’s ability to sell the products in question and require the payment of money damages and future royalties.
Risks related to product liability, litigation and regulatory activity
•
Product efficacy or safety concerns, whether or not based on scientific evidence, potentially resulting in product withdrawals, recalls, regulatory action on the part of the United States Food and Drug Administration (U.S. FDA) (or international counterparts), declining sales, reputational damage, increased litigation expense and share price impact;
•
The impact, including declining sales and reputational damage, of significant litigation or government action adverse to the Company, including product liability claims and allegations related to pharmaceutical marketing practices and contracting strategies;
•
The impact of an adverse judgment or settlement and the adequacy of reserves related to legal proceedings, including patent litigation, product liability, personal injury claims, securities class actions, government investigations, employment and other legal proceedings;
•
Increased scrutiny of the healthcare industry by government agencies and state attorneys general resulting in investigations and prosecutions, which carry the risk of significant civil and criminal penalties, including, but not limited to, debarment from government business;
•
Failure to meet compliance obligations in compliance agreements with governments or government agencies, which could result in significant sanctions;
•
Potential changes to applicable laws and regulations affecting United States and international operations, including relating to: approval of new products; licensing and patent rights; sales and promotion of healthcare products; access to, and reimbursement and pricing for, healthcare products and services; environmental protection; and sourcing of raw materials;
•
Compliance with local regulations and laws that may restrict the Company’s ability to manufacture or sell its products in relevant markets, including requirements to comply with medical device reporting regulations and other requirements such as the European Union’s Medical Devices Regulation;
•
Changes in domestic and international tax laws and regulations, increasing audit scrutiny by tax authorities around the world may cause exposures to additional tax liabilities potentially in excess of existing reserves; and
•
The issuance of new or revised accounting standards by the Financial Accounting Standards Board and regulations by the Securities and Exchange Commission.
Risks related to the Company’s strategic initiatives and healthcare market trends
•
Pricing pressures resulting from trends toward healthcare cost containment, including the continued consolidation among healthcare providers and other market participants, trends toward managed care, the shift toward governments increasingly becoming the primary payors of healthcare expenses, significant new entrants to the healthcare markets seeking to reduce costs and government pressure on companies to voluntarily reduce costs and price increases;
•
Restricted spending patterns of individual, institutional and governmental purchasers of healthcare products and services due to economic hardship and budgetary constraints;
•
Challenges to the Company’s ability to realize its strategy for growth including through externally sourced innovations, such as development collaborations, strategic acquisitions, licensing and marketing agreements, and the potential heightened costs of any such external arrangements due to competitive pressures;
•
The potential that the expected strategic benefits and opportunities from any planned or completed acquisition or divestiture by the Company may not be realized or may take longer to realize than expected; and
•
The potential that the expected benefits and opportunities related to past and ongoing restructuring actions may not be realized or may take longer to realize than expected.
Risks related to economic conditions, financial markets and operating internationally
•
The risks associated with global operations on the Company and its customers and suppliers, including foreign governments in countries in which the Company operates;
•
The impact of inflation and fluctuations in interest rates and currency exchange rates and the potential effect of such fluctuations on revenues, expenses and resulting margins;
•
Potential changes in export/import and trade laws, regulations and policies of the United States and other countries, including any increased trade restrictions or tariffs and potential drug reimportation legislation, and the impact of such changes on raw material prices, supply chains market volatility and the pace of product development;
•
The impact on international operations from financial instability in international economies, sovereign risk, possible imposition of governmental controls and restrictive economic policies, and unstable international governments and legal systems;
•
The impact of global public health crises and pandemics;
•
Changes to global climate, extreme weather and natural disasters that could affect demand for the Company’s products and services, cause disruptions in manufacturing and distribution networks, alter the availability of goods and services within the supply chain, and affect the overall design and integrity of the Company’s products and operations;
•
The impact of global or economic changes or events, including global tensions and war; and
•
The impact of armed conflicts and terrorist attacks in the United States and other parts of the world, including social and economic disruptions and instability of financial and other markets.
Risks related to supply chain and operations
•
Difficulties and delays in manufacturing, internally, through third-party providers or otherwise within the supply chain, that may lead to voluntary or involuntary business interruptions or shutdowns, product shortages, withdrawals or suspensions of products from the market, and potential regulatory action;
•
Interruptions and breaches of the Company’s information technology systems or those of the Company’s vendors, which could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action;
•
Reliance on global supply chains and production and distribution processes that are complex and subject to increasing regulatory requirements that may adversely affect supply, sourcing and pricing of materials used in the Company’s products; and
•
The potential that the expected benefits and opportunities related to restructuring actions may not be realized or may take longer to realize than expected, including due to any required approvals from applicable regulatory authorities.
Investors also should carefully read the Risk Factors described in Item 1A of the Company's Annual Report on Form 10-K for the fiscal year ended December 29, 2024, for a description of certain risks that could, among other things, cause the Company’s actual results to differ materially from those expressed in its forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described above to be a complete statement of all potential risks and uncertainties. The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments.
Table of Contents
Part I — Financial information
Item 1 — Financial statements
Johnson & Johnson and subsidiaries consolidated balance sheets
(Unaudited; Dollars in Millions Except Share and Per Share Data)
June 29, 2025 December 29, 2024
Assets
Current assets:
Cash and cash equivalents (Note 4) $ 18,577 24,105
Marketable securities 303 417
Accounts receivable, trade, less allowances $ 185 (2024, $ 167 ) 17,846 14,842
Inventories (Note 2) 13,412 12,444
Prepaid expenses and other 4,360 4,085
Total current assets 54,498 55,893
Property, plant and equipment at cost 52,472 48,768
Less: accumulated depreciation ( 30,523 ) ( 28,250 )
Property, plant and equipment, net 21,949 20,518
Intangible assets, net (Note 3) 49,835 37,618
Goodwill (Note 3) 48,117 44,200
Deferred taxes on income (Note 5) 6,801 10,461
Other assets 12,189 11,414
Total assets $ 193,389 180,104
Liabilities and shareholders’ equity
Current liabilities:
Loans and notes payable $ 11,526 5,983
Accounts payable 9,464 10,311
Accrued liabilities 7,404 8,549
Accrued rebates, returns and promotions 20,823 17,580
Accrued compensation and employee related obligations 3,298 4,126
Accrued taxes on income (Note 5) 1,665 3,772
Total current liabilities 54,180 50,321
Long-term debt (Note 4) 39,235 30,651
Deferred taxes on income (Note 5) 3,799 2,448
Employee related obligations (Note 6) 7,021 7,255
Long-term taxes payable (Note 5) 418 390
Other liabilities 10,263 17,549
Total liabilities $ 114,916 108,614
Commitments and Contingencies (Note 11)
Shareholders’ equity:
Common stock — par value $ 1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) $ 3,120 3,120
Accumulated other comprehensive income (loss) (Note 7) ( 14,305 ) ( 11,741 )
Retained earnings and Additional paid-in capital 165,371 155,791
Less: common stock held in treasury, at cost ( 713,064,000 and 712,921,000 shares) 75,713 75,680
Total shareholders’ equity $ 78,473 71,490
Total liabilities and shareholders’ equity $ 193,389 180,104

See Notes to Consolidated Financial Statements
Form 10-Q 1

Table of Contents
Johnson & Johnson and subsidiaries consolidated statements of earnings
(Unaudited; Dollars & Shares in Millions Except Per Share Amounts)
Fiscal Second Quarter Ended
June 29, 2025 Percent to Sales June 30, 2024 Percent to Sales
Sales to customers (Note 9) $ 23,743 100.0 % $ 22,447 100.0 %
Cost of products sold 7,628 32.1 6,869 30.6
Gross profit 16,115 67.9 15,578 69.4
Selling, marketing and administrative expenses 5,889 24.8 5,681 25.3
Research and development expense 3,516 14.8 3,440 15.3
In-process research and development impairments — — 194 0.9
Interest income ( 260 ) ( 1.1 ) ( 395 ) ( 1.8 )
Interest expense, net of portion capitalized 308 1.3 270 1.2
Other (income) expense, net 107 0.5 653 2.9
Restructuring (Note 12) 64 0.3 ( 13 ) 0.0
Earnings before provision for taxes on income 6,491 27.3 5,748 25.6
Provision for taxes on income (Note 5) 954 4.0 1,062 4.7
Net earnings $ 5,537 23.3 % $ 4,686 20.9 %
Net earnings per share (Note 8)
Basic $ 2.30 $ 1.95
Diluted $ 2.29 $ 1.93
Avg. shares outstanding
Basic 2,406.3 2,406.8
Diluted 2,419.1 2,422.0

See Notes to Consolidated Financial Statements
2

Table of Contents
Johnson & Johnson and subsidiaries consolidated statements of earnings
(Unaudited; Dollars & Shares in Millions Except Per Share Amounts)
Fiscal Six Months Ended
June 29, 2025 Percent to Sales June 30, 2024 Percent to Sales
Sales to customers (Note 9) $ 45,636 100.0 % $ 43,830 100.0 %
Cost of products sold 14,985 32.8 13,380 30.5
Gross profit 30,651 67.2 30,450 69.5
Selling, marketing and administrative expenses 11,001 24.1 10,938 25.0
Research and development expense 6,741 14.8 6,982 16.0
In-process research and development impairments — — 194 0.4
Interest income ( 592 ) ( 1.3 ) ( 759 ) ( 1.8 )
Interest expense, net of portion capitalized 512 1.1 425 1.0
Other (income) expense, net ( 7,214 ) ( 15.8 ) 3,057 7.0
Restructuring (Note 12) 81 0.2 151 0.3
Earnings before provision for taxes on income 20,122 44.1 9,462 21.6
Provision for taxes on income (Note 5) 3,586 7.9 1,521 3.5
Net earnings $ 16,536 36.2 % $ 7,941 18.1 %
Net earnings per share (Note 8)
Basic $ 6.87 $ 3.30
Diluted $ 6.82 $ 3.27
Avg. shares outstanding
Basic 2,406.7 2,407.5
Diluted 2,423.3 2,428.5

See Notes to Consolidated Financial Statements
Form 10-Q 3

Table of Contents
Johnson & Johnson and subsidiaries consolidated statements of comprehensive income
(Unaudited; Dollars in Millions)
Fiscal Second Quarter Ended Fiscal Six Months Ended
June 29, 2025 June 30, 2024 June 29, 2025 June 30, 2024
Net earnings $ 5,537 4,686 $ 16,536 7,941
Other comprehensive income (loss), net of tax
Foreign currency translation ( 3,164 ) ( 389 ) ( 3,739 ) 1,734
Securities:
Unrealized holding gain (loss) arising during period ( 1 ) ( 1 ) ( 1 ) 1
Net change ( 1 ) ( 1 ) ( 1 ) 1
Employee benefit plans:
Prior service cost amortization during period ( 36 ) ( 34 ) ( 71 ) ( 50 )
Gain (loss) amortization during period 79 43 156 111
Net change 43 9 85 61
Derivatives & hedges:
Unrealized gain (loss) arising during period 25 75 ( 117 ) ( 92 )
Reclassifications to earnings 532 ( 179 ) 1,208 ( 430 )
Net change 557 ( 104 ) 1,091 ( 522 )
Other comprehensive income (loss) ( 2,565 ) ( 485 ) ( 2,564 ) 1,274
Comprehensive income $ 2,972 4,201 $ 13,972 9,215

See Notes to Consolidated Financial Statements
The tax cost/(benefit) effects in other comprehensive income for the fiscal second quarter were as follows for 2025 and 2024, respectively: Foreign Currency Translation: $ 824 million and $( 65 ) million; Employee Benefit Plans: $ 10 million and $ 1 million; Derivatives & Hedges: $ 148 million and $( 28 ) million.
The tax cost/(benefit) effects in other comprehensive income/(loss) for the fiscal six months were as follows for 2025 and 2024, respectively: Foreign Currency Translation: $ 1.2 billion and $( 684 ) million; Employee Benefit Plans: $ 21 million and $( 41 ) million; Derivatives & Hedges: $ 290 million and $( 139 ) million.

4

Table of Contents
Johnson & Johnson and subsidiaries consolidated statements of equity
(Unaudited; Dollars in Millions)
Fiscal Second Quarter Ended June 29, 2025
Total Retained Earnings and Additional Paid-in Capital Accumulated Other Comprehensive Income (AOCI) Common Stock Issued Amount Treasury Stock Amount
Balance, March 30, 2025 $ 78,109 162,635 ( 11,740 ) 3,120 ( 75,906 )
Net earnings 5,537 5,537 — — —
Cash dividends paid ($ 1.30 per share) ( 3,129 ) ( 3,129 ) — — —
Employee compensation and stock option plans 519 328 — — 191
Repurchase of common stock (including excise tax) 2 — — — 2
Other comprehensive income (loss), net of tax ( 2,565 ) — ( 2,565 ) — —
Balance, June 29, 2025 $ 78,473 165,371 ( 14,305 ) 3,120 ( 75,713 )

Fiscal Six Months Ended June 29, 2025
Total Retained Earnings and Additional Paid-in Capital Accumulated Other Comprehensive Income (AOCI) Common Stock Issued Amount Treasury Stock Amount
Balance, December 29, 2024 $ 71,490 155,791 ( 11,741 ) 3,120 ( 75,680 )
Net earnings 16,536 16,536 — — —
Cash dividends paid ($ 2.54 per share) ( 6,118 ) ( 6,118 ) — — —
Employee compensation and stock option plans 1,256 ( 838 ) — — 2,094
Repurchase of common stock (including excise tax) ( 2,127 ) — — — ( 2,127 )
Other comprehensive income (loss), net of tax ( 2,564 ) — ( 2,564 ) — —
Balance, June 29, 2025 $ 78,473 165,371 ( 14,305 ) 3,120 ( 75,713 )

Form 10-Q 5

Table of Contents
Fiscal Second Quarter Ended June 30, 2024
Total Retained Earnings and Additional Paid-in Capital Accumulated Other Comprehensive Income Common Stock Issued Amount Treasury Stock Amount
Balance, March 31, 2024 $ 70,020 153,378 ( 10,768 ) 3,120 ( 75,710 )
Net earnings 4,686 4,686 — — —
Cash dividends paid ($ 1.24 per share) ( 2,985 ) ( 2,985 ) — — —
Employee compensation and stock option plans 438 281 — — 157
Repurchase of common stock ( 136 ) — — — ( 136 )
Other comprehensive income (loss), net of tax ( 485 ) — ( 485 ) — —
Balance, June 30, 2024 $ 71,538 155,360 ( 11,253 ) 3,120 ( 75,689 )

Fiscal Six Months Ended June 30, 2024
Total Retained Earnings and Additional Paid-in Capital Accumulated Other Comprehensive Income Common Stock Issued Amount Treasury Stock Amount
Balance, December 31, 2023 $ 68,774 153,843 ( 12,527 ) 3,120 ( 75,662 )
Net earnings 7,941 7,941 — — —
Cash dividends paid ($ 2.43 per share) ( 5,854 ) ( 5,854 ) — — —
Employee compensation and stock option plans 1,015 ( 570 ) — — 1,585
Repurchase of common stock ( 1,611 ) — — — ( 1,611 )
Other ( 1 ) — — — ( 1 )
Other comprehensive income (loss), net of tax 1,274 — 1,274 — —
Balance, June 30, 2024 $ 71,538 155,360 ( 11,253 ) 3,120 ( 75,689 )

See Notes to Consolidated Financial Statements
6

Table of Contents
Johnson & Johnson and subsidiaries consolidated statements of cash flows
(Unaudited; Dollars in Millions)
Fiscal Six Months Ended
June 29, 2025 June 30, 2024
Cash flows from operating activities
Net earnings $ 16,536 7,941
Adjustments to reconcile net earnings to cash flows from operating activities:
Depreciation and amortization of property and intangibles 3,715 3,597
Stock based compensation 698 643
Asset write-downs 30 379
Charges for purchase of in-process research and development assets 92 —
Net gain on sale of assets/businesses ( 74 ) ( 223 )
Deferred tax provision 2,997 ( 2,257 )
Credit losses and accounts receivable allowances 3 —
Changes in assets and liabilities, net of effects from acquisitions and divestitures:
Increase in accounts receivable ( 2,283 ) ( 1,163 )
Increase in inventories ( 656 ) ( 739 )
(Decrease) / Increase in accounts payable and accrued liabilities ( 886 ) 449
(Increase)/Decrease in other current and non-current assets ( 6,194 ) 3,731
Decrease in other current and non-current liabilities ( 5,926 ) ( 3,068 )
Net cash flows from operating activities 8,052 9,290
Cash flows from investing activities
Additions to property, plant and equipment ( 1,838 ) ( 1,783 )
Proceeds from the disposal of assets/businesses, net (Note 10) 332 573
Acquisitions, net of cash acquired (Note 10) ( 14,458 ) ( 14,807 )
Acquired in-process research and development assets / related milestones (Note 10) ( 369 ) —
Purchases of investments ( 431 ) ( 1,184 )
Sales of investments 953 1,706
Credit support agreements activity, net ( 2,684 ) 1,430
Other (including capitalized licenses and milestones) ( 66 ) ( 86 )
Net cash used by investing activities ( 18,561 ) ( 14,151 )
Cash flows from financing activities
Dividends to shareholders ( 6,118 ) ( 5,854 )
Repurchase of common stock ( 2,127 ) ( 1,611 )
Proceeds from short-term debt, net 9,349 13,976
Repayment of short-term debt, net ( 5,058 ) ( 3,915 )
Proceeds from long-term debt, net of issuance costs 9,138 6,659
Repayment of long-term debt ( 754 ) ( 803 )
Proceeds from the exercise of stock options/employee withholding tax on stock awards, net 557 290
Credit support agreements activity, net ( 271 ) 281
Settlement of convertible debt acquired from Shockwave — ( 970 )
Other 41 37
Net cash from financing activities 4,757 8,090
Effect of exchange rate changes on cash and cash equivalents 224 ( 210 )
(Decrease) / Increase in cash and cash equivalents ( 5,528 ) 3,019
Cash and cash equivalents, beginning of period 24,105 21,859
Cash and cash equivalents, end of period 18,577 24,878

See Notes to Consolidated Financial Statements
Form 10-Q 7

Table of Contents
Notes to consolidated financial statements
Note 1
—
The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson & Johnson and its subsidiaries (the Company) and related notes as contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 29, 2024. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented.
Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.
New accounting standards
The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company’s Annual Report on Form 10-K for the fiscal year ended December 29, 2024.
Recently adopted accounting standards
There were no new material accounting standards adopted in the fiscal six months of 2025.
Recently issued accounting standards
There were no new material accounting standards issued in the fiscal six months of 2025.
Supplier finance program obligations
The Company has agreements for supplier finance programs with third-party financial institutions. These programs provide enrolled suppliers the ability to finance payment obligations from the Company with the third-party financial institutions. The Company is not a party to the arrangements between the suppliers and the third-party financial institutions. The Company’s obligations to its suppliers, including amounts due, and scheduled payment dates (which have general payment terms of
90
days), are not affected by a participating supplier’s decision to join in the program.
Confirmed obligations under the program as of June 29, 2025, and December 29, 2024, were $
0.7
 billion and $
0.8
 billion, respectively. The obligations are presented as Accounts payable on the Consolidated Balance Sheets.

Note 2 —
Inventories
(Dollars in Millions) June 29, 2025 December 29, 2024
Raw materials and supplies $ 2,389 2,337
Goods in process 3,971 2,815
Finished goods 7,052 7,292
Total inventories $ 13,412 12,444

8

Table of Contents
Note 3 —
Intangible assets and goodwill
Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2024. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted.
(Dollars in Millions) June 29, 2025 December 29, 2024
Intangible assets with definite lives:
Patents and trademarks — gross $ 53,272 44,695
Less accumulated amortization ( 30,756 ) ( 26,124 )
Patents and trademarks — net $ 22,516 18,571
Customer relationships and other intangibles — gross 21,910 20,310
Less accumulated amortization ( 14,487 ) ( 13,544 )
Customer relationships and other intangibles — net (1) $ 7,423 6,766
Intangible assets with indefinite lives:
Purchased in-process research and development 19,896 12,281
Total intangible assets — net $ 49,835 37,618

(1)
The majority is comprised of customer relationships
Goodwill as of June 29, 2025 was allocated by segment of business as follows:
(Dollars in Millions) Innovative Medicine MedTech Total
Goodwill at December 29, 2024 $ 10,692 33,508 44,200
Goodwill, related to acquisitions 2,876 — 2,876
Goodwill, related to divestitures — ( 29 ) ( 29 )
Currency translation/Other 758 312 1,070
Goodwill at June 29, 2025 $ 14,326 33,791 48,117

    
The weighted average amortization period for patents and trademarks is approximately
13
years. The weighted average amortization period for customer relationships and other intangible assets is approximately
19
years. The amortization expense of amortizable intangible assets included in the cost of products sold was $
1.3
 billion and $
1.1
billion for the fiscal second quarters ended June 29, 2025 and June 30, 2024, respectively. The amortization expense of amortizable intangible assets included in the cost of products sold was $
2.4
 billion and $
2.2
 billion for the fiscal six months ended June 29, 2025 and June 30, 2024, respectively.
The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:
(Dollars in Millions)
2025 2026 2027 2028 2029
$ 4,500 4,000 3,400 2,700 2,600

See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.
Form 10-Q 9

Table of Contents
Note 4 —
Fair value measurements
The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges.
Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities.
The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of June 29, 2025, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $
5.2
billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of June 29, 2025, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $
47.7
 billion, $
40.9
 billion and $
9.0
 billion, respectively. As of December 29, 2024, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $
45.1
billion, $
40.5
billion and $
9.0
billion, respectively.
All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.
The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction.
Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued.
The Company designated its Euro denominated notes with due dates ranging from 2028 to 2055 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates.
As of June 29, 2025, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $
0.7
 billion after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is
18
months, excluding interest rate contracts and net investment hedge contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.
10

Table of Contents
The following table is a summary of the activity related to derivatives and hedges for the fiscal second quarters ended June 29, 2025 and June 30, 2024, net of tax:
June 29, 2025 June 30, 2024
(Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense
The effects of fair value, net investment and cash flow hedging:
Gain (Loss) on fair value hedging relationship:
Interest rate swaps contracts:
Hedged items $ — — — 52 — — — — ( 53 ) —
Derivatives designated as hedging instruments — — — ( 52 ) — — — — 53 —
Gain (Loss) on net investment hedging relationship:
Cross currency interest rate swaps contracts:
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing — — — 48 — — — — 33 —
Amount of gain or (loss) recognized in AOCI — — — 48 — — — — 33 —
Gain (Loss) on cash flow hedging relationship:
Forward foreign exchange contracts:
Amount of gain or (loss) reclassified from AOCI into income 2 ( 132 ) ( 16 ) — ( 3 ) ( 1 ) 94 8 — 3
Amount of gain or (loss) recognized in AOCI 11 466 ( 72 ) — ( 29 ) 2 66 11 — 1
Cross currency interest rate swaps contracts:
Amount of gain or (loss) reclassified from AOCI into income — — — 76 — — — — 42 —
Amount of gain or (loss) recognized in AOCI $ — — — 108 — — — — ( 38 ) —

Form 10-Q 11

Table of Contents
The following table is a summary of the activity related to derivatives and hedges for the fiscal six months ended June 29, 2025 and June 30, 2024, net of tax:
June 29, 2025 June 30, 2024
(Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense
The effects of fair value, net investment and cash flow hedging:
Gain (Loss) on fair value hedging relationship:
Interest rate swaps contracts:
Hedged items $ — — — 240 — — — — ( 45 ) —
Derivatives designated as hedging instruments — — — ( 240 ) — — — — 45 —
Gain (Loss) on net investment hedging relationship:
Cross currency interest rate swaps contracts:
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing — — — 98 — — — — 67 —
Amount of gain or (loss) recognized in AOCI — — — 98 — — — — 67 —
Gain (Loss) on cash flow hedging relationship:
Forward foreign exchange contracts:
Amount of gain or (loss) reclassified from AOCI into income 1 ( 122 ) ( 15 ) — ( 3 ) — 259 12 — 1
Amount of gain or (loss) recognized in AOCI 14 571 ( 108 ) — ( 40 ) ( 1 ) 47 33 — 5
Cross currency interest rate swaps contracts:
Amount of gain or (loss) reclassified from AOCI into income — — — 158 — — — — 91 —
Amount of gain or (loss) recognized in AOCI $ — — — 673 — — — — ( 243 ) —

12

Table of Contents
As of June 29, 2025, and December 29, 2024, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges:
Line item in the Consolidated Balance Sheet in which the hedged item is included Carrying Amount of the Hedged Liability Cumulative Amount of Fair Value Hedging Gain/ (Loss) Included in the Carrying Amount of the Hedged Liability
(Dollars in Millions) June 29, 2025 December 29, 2024 June 29, 2025 December 29, 2024
Long-term Debt $ 8,209 7,935 ( 820 ) ( 1,132 )

The following table is the effect of derivatives not designated as hedging instruments for the fiscal second quarters ended and fiscal six months ended 2025 and 2024:
Gain/(Loss) Recognized In Income on Derivative Gain/(Loss) Recognized In Income on Derivative
(Dollars in Millions) Location of Gain /(Loss) Recognized in Income on Derivative Fiscal Second Quarter Ended Fiscal Six Months Ended
Derivatives Not Designated as Hedging Instruments June 29, 2025 June 30, 2024 June 29, 2025 June 30, 2024
Foreign Exchange Contracts Other (income) expense $( 19 ) 20 43 45

The following table is the effect of net investment hedges for the fiscal second quarters ended in 2025 and 2024:
Gain/(Loss) Recognized In Accumulated OCI Location of Gain or (Loss) Reclassified from Accumulated OCI Into Income Gain/(Loss) Reclassified From Accumulated OCI Into Income
(Dollars in Millions) June 29, 2025 June 30, 2024 June 29, 2025 June 30, 2024
Debt $( 803 ) 46 Interest (income) expense — —
Cross Currency interest rate swaps $( 700 ) 92 Interest (income) expense — —

The following table is the effect of net investment hedges for the fiscal six months ended in 2025 and 2024
Gain/(Loss) Recognized In Accumulated OCI Location of Gain or (Loss) Reclassified from Accumulated OCI Into Income Gain/(Loss) Reclassified From Accumulated OCI Into Income
(Dollars in Millions) June 29, 2025 June 30, 2024 June 29, 2025 June 30, 2024
Debt $( 1,119 ) 130 Interest (income) expense — —
Cross Currency interest rate swaps $ 140 820 Interest (income) expense — —

Form 10-Q 13

Table of Contents
The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company has elected to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.
The following table is a summary of the activity related to equity investments:
December 29, 2024 June 29, 2025
(Dollars in Millions) Carrying Value Changes in Fair Value Reflected in Net Income (1) (Sales)/ Purchases/Other (2) Carrying Value Non Current Other Assets
Equity Investments with readily determinable value $ 451 ( 57 ) 59 453 453
Equity Investments without readily determinable value $ 773 ( 26 ) 76 823 823

(1)
Recorded in Other (income)/expense, net
(2)
Other includes impact of currency
Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest.
The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company’s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.
The following three levels of inputs are used to measure fair value:
Level 1 — Quoted prices in active markets for identical assets and liabilities.
Level 2 — Significant other observable inputs.
Level 3 — Significant unobservable inputs.
14

Table of Contents
The Company’s significant financial assets and liabilities measured at fair value as of June 29, 2025 and December 29, 2024 were as follows:
June 29, 2025 December 29, 2024
(Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1)
Derivatives designated as hedging instruments:
Assets:
Forward foreign exchange contracts $ — 1,006 — 1,006 660
Interest rate contracts (2) — 431 — 431 1,484
Total — 1,437 — 1,437 2,144
Liabilities:
Forward foreign exchange contracts — 774 — 774 794
Interest rate contracts (2) — 6,234 — 6,234 3,753
Total — 7,008 — 7,008 4,547
Derivatives not designated as hedging instruments:
Assets:
Forward foreign exchange contracts — 57 — 57 50
Liabilities:
Forward foreign exchange contracts — 72 — 72 17
Other Investments:
Equity investments (3) 453 — — 453 451
Debt securities (4) — 2,094 — 2,094 7,216
Other Liabilities:
Contingent consideration (5) $ — — 1,157 1,157 1,217

Gross to Net Derivative Reconciliation June 29, 2025 December 29, 2024
(Dollars in Millions)
Total Gross Assets $ 1,494 2,194
Credit Support Agreement (CSA) ( 1,471 ) ( 2,172 )
Total Net Asset 23 22
Total Gross Liabilities 7,080 4,564
Credit Support Agreement (CSA) ( 6,666 ) ( 4,412 )
Total Net Liabilities $ 414 152

Summarized information about changes in liabilities for contingent consideration for the fiscal second quarters ended June 29, 2025 and June 30, 2024 is as follows:
June 29, 2025 June 30, 2024
(Dollars in Millions)
Beginning Balance $ 1,217 1,092
Changes in estimated fair value (6) ( 60 ) 44
Additions — 112
Payments — —
Ending Balance $ 1,157 1,248

(1)
2024 assets and liabilities are all classified as Level 2 with the exception of equity investments of $
451
million, which are classified as Level 1 and contingent consideration of $
1,217
million, classified as Level 3.
(2)
Includes cross currency interest rate swaps and interest rate swaps.
(3)
Classified as non-current other assets.
Form 10-Q 15

Table of Contents
(4)
Classified within cash equivalents and current marketable securities.
(5)
Includes $
1,107
million and $
1,217
million classified as non-current other liabilities as of June 29, 2025 and December 29, 2024, respectively. Includes $
50
million classified as current liabilities as of June 29, 2025.
(6)
Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense.

The Company's cash, cash equivalents and current marketable securities as of June 29, 2025 comprised:
(Dollars in Millions) Carrying Amount Unrealized Gain Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities
Cash $ 3,246 — 3,246 3,246 —
U.S. reverse repurchase agreements 8,040 — 8,040 8,040 —
Money market funds 4,637 — 4,637 4,637 —
Time deposits (1) 863 — 863 863 —
Subtotal 16,786 — 16,786 16,786 —
U.S. Gov’t securities 1,673 — 1,673 1,659 14
Other sovereign securities 193 — 193 94 99
Corporate debt securities 228 — 228 38 190
Subtotal available for sale debt (2) $ 2,094 — 2,094 1,791 303
Total cash, cash equivalents and current marketable securities $ 18,880 — 18,880 18,577 303

(1)
Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings.
(2)
Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.
As of the fiscal year ended December 29, 2024, the carrying amount of cash, cash equivalents and current marketable securities was approximately the same as the estimated fair value.
Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs.
The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as current marketable securities.
The contractual maturities of the available for sale securities as of June 29, 2025 are as follows:
(Dollars in Millions) Cost Basis Fair Value
Due within one year $ 2,075 2,075
Due after one year through five years 19 19
Due after five years through ten years — —
Total debt securities $ 2,094 2,094

16

Table of Contents
Financial instruments not measured at fair value
The following financial liabilities are held at carrying amount on the consolidated balance sheet as of June 29, 2025:
(Dollars in Millions) Carrying Amount Estimated Fair Value
Financial Liabilities
Current Debt $ 11,526 11,495
Non-Current Debt
2.95 % Notes due 2027 950 984
0.95 % Notes due 2027 1,478 1,410
4.50 % Notes due 2027 (1) 749 757
2.90 % Notes due 2028 1,498 1,460
1.150 % Notes due 2028 ( 750 MM Euro 1.1704 ) 881 843
4.55 % Notes due 2028 (1) 748 762
4.80 % Notes due 2029 1,146 1,181
6.95 % Notes due 2029 299 334
2.70 % Notes due 2029 ( 600 MM Euro 1.1704 ) (1) 706 708
1.30 % Notes due 2030 1,676 1,521
4.70 % Notes due 2030 (1) 995 1,022
4.90 % Notes due 2031 1,146 1,189
3.20 % Notes due 2032 ( 700 MM Euro 1.1704 ) 821 834
4.85 % Notes due 2032 (1) 1,242 1,281
4.95 % Notes due 2033 499 517
4.375 % Notes due 2033 853 847
3.050 % Notes due 2033 ( 700 MM Euro 1.1704 ) (1) 822 822
4.95 % Notes due 2034 847 880
1.650 % Notes due 2035 ( 1.5 B Euro 1.1704 ) 1,756 1,528
5.00 % Notes due 2035 (1) 1,244 1,282
3.35 % Notes due 2036 ( 800 MM Euro 1.1704 ) 937 939
3.587 % Notes due 2036 905 902
5.95 % Notes due 2037 994 1,103
3.625 % Notes due 2037 1,396 1,334
3.350 % Notes due 2037 ( 1.0 B Euro 1.1704 ) (1) 1,175 1,160
3.40 % Notes due 2038 993 857
5.85 % Notes due 2038 697 761
4.50 % Notes due 2040 542 523
2.10 % Notes due 2040 885 684
4.85 % Notes due 2041 298 291
4.50 % Notes due 2043 496 459
3.55 % Notes due 2044 ( 1.0 B Euro 1.1704 ) 1,103 1,135
3.60 % Notes due 2045 ( 700 MM Euro 1.1704 ) (1) 819 792
3.73 % Notes due 2046 1,979 1,592
3.75 % Notes due 2047 863 798
3.50 % Notes due 2048 744 567
2.25 % Notes due 2050 851 580
5.25 % Notes due 2054 843 837

Form 10-Q 17

Table of Contents
3.70 % Notes due 2055 ( 1.0 B Euro 1.1704 ) (1) 1,172 1,118
2.45 % Notes due 2060 1,102 694
Other 85 88
Total Non-Current Debt $ 39,235 37,376

(1)
In the fiscal first quarter of 2025, the Company issued senior unsecured notes for approximately $
9.2
 billion. The net proceeds from this offering were used to fund the Intra-Cellular Therapies, Inc. acquisition which closed on April 2, 2025, and for general corporate purposes.

The weighted average effective interest rate on non-current debt is
3.57
%.
The excess of the carrying value over the estimated fair value of debt was $
2.0
billion at December 29, 2024.
Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.
The current debt balance as of June 29, 2025, includes $
8.5
 billion of commercial paper which has a weighted average interest rate of
4.28
% and a weighted average maturity of approximately
two months
.

Note 5 —
Income taxes
The worldwide effective income tax rates for the fiscal six months of 2025 and 2024 were
17.8
% and
16.1
%, respectively.
The increase in the worldwide effective tax rate is primarily due to more income in higher tax jurisdictions, specifically in the U.S. In the fiscal six months of 2025 the Company reversed previously accrued reserves of approximately $
7.0
 billion for the Talc settlement proposal versus a charge of $
3.0
 billion recorded in the fiscal six months of 2024 for the Talc settlement proposal. Both were recorded at an effective rate for U.S. federal and state tax of approximately
22
% (for further information see Note 11 to the Consolidated Financial Statements). Additionally in the fiscal six months of 2025, the effective tax rate benefited primarily from changes in uncertain international tax positions due to expiration of statute of limitations.
Subsequent to the end of the fiscal second quarter, on July 4, 2025, the United States enacted into law new tax legislation, the One Big Beautiful Bill Act, (OBBBA). The OBBBA includes provisions modifying the corporate income tax code, including the immediate expensing of domestic research and development expenditures for tax purposes, 100% bonus depreciation for qualified assets, and an increase in the statutory tax rate on foreign earnings from 10.5% to 12.6% (effective in the fiscal year 2026). The law also renamed the provision for taxes on foreign earnings from Global Intangible Low-Taxed Income (GILTI) to Net Controlled Foreign Corporation (CFC) Tested Income (NCTI). The Company has elected to account for GILTI, now NCTI, under the deferred method. The deferred tax amounts recorded are based on the evaluation of temporary differences that are expected to reverse as NCTI is incurred in future periods. As a result, the Company will remeasure its deferred tax balances related to NCTI for the changes in the tax rate and will record an adjustment to this balance in the fiscal third quarter. The Company is still assessing this impact but is estimating this one-time re-measurement cost to be approximately $
1.0
 billion.
As of June 29, 2025, the Company had approximately $
2.2
billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the Internal Revenue Service has completed its audit for the tax years through 2016 and the audit for tax years 2017 through 2020 is ongoing.
In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2013. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States.

18

Table of Contents
Note 6 —
Pensions and other benefit plans
Components of net periodic benefit cost
Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans include the following components:
Fiscal Second Quarter Ended Fiscal Six Months Ended
Retirement Plans Other Benefit Plans Retirement Plans Other Benefit Plans
(Dollars in Millions) June 29, 2025 June 30, 2024 June 29, 2025 June 30, 2024 June 29, 2025 June 30, 2024 June 29, 2025 June 30, 2024
Service cost $ 219 222 72 69 433 446 144 138
Interest cost 356 351 53 52 707 703 107 104
Expected return on plan assets ( 599 ) ( 639 ) ( 1 ) ( 1 ) ( 1,186 ) ( 1,281 ) ( 3 ) ( 3 )
Amortization of prior service cost/(credit) ( 46 ) ( 46 ) ( 1 ) ( 1 ) ( 92 ) ( 92 ) ( 1 ) ( 1 )
Recognized actuarial (gains)/losses 85 44 15 13 168 87 31 26
Curtailments and settlements — ( 8 ) — — — ( 8 ) — —
Special termination benefits 1 — — — 1 — — —
Net periodic benefit cost/(credit) $ 16 ( 76 ) 138 132 31 ( 145 ) 278 264

The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, and Selling, marketing and administrative expenses. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings.
Company contributions
For the fiscal six months ended June 29, 2025, the Company contributed $
69
million and $
8
million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.
Form 10-Q 19

Table of Contents
Note 7 —
Accumulated other comprehensive income
Components of other comprehensive income/(loss) consist of the following:
(Dollars in Millions) Foreign Currency Translation Gain/ (Loss) On Securities Employee Benefit Plans Gain/ (Loss) On Derivatives & Hedges Total Accumulated Other Comprehensive Income/(Loss)
December 29, 2024 $( 8,441 ) 1 ( 1,551 ) ( 1,750 ) ( 11,741 )
Net change ( 3,739 ) ( 1 ) 85 1,091 ( 2,564 )
June 29, 2025 ( 12,180 ) 0 ( 1,466 ) ( 659 ) ( 14,305 )

Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income.
Details on reclassifications out of Accumulated Other Comprehensive Income:
Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.
Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details.
Gain/(Loss) On Derivatives & Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.

Note 8 —
Earnings per share
The following is a reconciliation of basic net earnings per share to diluted net earnings per share:
Fiscal Second Quarter Ended Fiscal Six Months Ended
(Shares in Millions) June 29, 2025 June 30, 2024 June 29, 2025 June 30, 2024
Basic net earnings per share $ 2.30 1.95 6.87 3.30
Average shares outstanding — basic 2,406.3 2,406.8 2,406.7 2,407.5
Potential shares exercisable under stock option plans 64.6 62.6 67.0 79.3
Less: shares which could be repurchased under treasury stock method ( 51.8 ) ( 47.4 ) ( 50.4 ) ( 58.3 )
Average shares outstanding — diluted 2,419.1 2,422.0 2,423.3 2,428.5
Diluted net earnings per share $ 2.29 1.93 6.82 3.27
(Shares in Millions)
The diluted net earnings per share calculation excluded the following number of shares related to stock options, as the exercise price of these options was greater than the average market value of the Company’s stock. 66.3 72.2 63.3 53.8

20

Table of Contents
Note 9 —
Segments of business and geographic areas
The Company is organized into
two
business segments: Innovative Medicine and MedTech.
The Company’s chief operating decision maker (CODM) is the Chief Executive Officer (Principal Executive Officer). For the Innovative Medicine and MedTech segments, the CODM uses segment income before tax to allocate resources (including employees, financial, and capital resources) for each segment predominantly in the annual forecasting process. The CODM considers planning-to-actual variances on a quarterly basis to assess performance and make decisions about allocating resources to the segments.
Sales by segment of business
Fiscal Second Quarter Ended Fiscal Six Months Ended
(Dollars in Millions) June 29, 2025 June 30, 2024 Percent Change June 29, 2025 June 30, 2024 Percent Change
INNOVATIVE MEDICINE
Oncology
U.S. $ 3,385 2,636 28.4 % $ 6,398 5,019 27.5 %
International 2,928 2,455 19.3 5,592 4,885 14.5
Worldwide 6,312 5,090 24.0 11,990 9,904 21.1
CARVYKTI
U.S. 358 167 * 676 307 *
International 81 20 * 132 36 *
Worldwide 439 186 * 808 343 *
DARZALEX
U.S. 2,017 1,641 23.0 3,846 3,105 23.9
International 1,521 1,237 23.0 2,930 2,465 18.9
Worldwide 3,539 2,878 23.0 6,776 5,570 21.7
ERLEADA
U.S. 378 318 18.6 670 603 11.0
International 530 418 27.0 1,009 822 22.9
Worldwide 908 736 23.4 1,679 1,425 17.8
IMBRUVICA
U.S. 239 246 ( 2.7 ) 474 511 ( 7.3 )
International 496 525 ( 5.4 ) 970 1,043 ( 6.9 )
Worldwide 735 770 ( 4.5 ) 1,444 1,554 ( 7.0 )
RYBREVANT/ LAZCLUZE (1)
U.S. 139 52 * 252 88 *
International 41 17 * 69 28 *
Worldwide 179 69 * 320 116 *
TALVEY
U.S. 82 59 38.0 150 109 36.7
International 24 9 * 42 17 *
Worldwide 106 69 55.0 192 127 52.0
TECVAYLI
U.S. 114 104 8.2 219 205 6.6
International 52 30 74.8 98 63 56.0
Worldwide 166 135 23.1 317 268 18.2

Form 10-Q 21

Table of Contents
Fiscal Second Quarter Ended Fiscal Six Months Ended
(Dollars in Millions) June 29, 2025 June 30, 2024 Percent Change June 29, 2025 June 30, 2024 Percent Change
ZYTIGA / abiraterone acetate
U.S. 6 11 ( 38.9 ) 13 20 ( 31.9 )
International 139 154 ( 9.8 ) 257 326 ( 21.1 )
Worldwide 145 165 ( 11.6 ) 270 346 ( 21.7 )
OTHER ONCOLOGY
U.S. 50 37 36.9 97 70 39.8
International 42 45 ( 8.7 ) 84 86 ( 2.5 )
Worldwide 93 83 11.7 182 156 16.4
Immunology
U.S. 2,505 2,978 ( 15.9 ) 4,701 5,431 ( 13.4 )
International 1,489 1,744 ( 14.6 ) 2,999 3,538 ( 15.2 )
Worldwide 3,993 4,722 ( 15.4 ) 7,700 8,969 ( 14.1 )
REMICADE
U.S. 283 231 22.5 597 497 20.1
U.S. Exports 34 35 ( 2.6 ) 44 62 ( 28.7 )
International 138 127 8.6 281 268 4.8
Worldwide 455 393 15.9 922 827 11.5
SIMPONI / SIMPONI ARIA
U.S. 305 267 14.0 597 521 14.4
International 387 270 43.1 753 569 32.2
Worldwide 690 537 28.6 1,349 1,091 23.7
STELARA
U.S. 1,078 1,855 ( 41.9 ) 2,059 3,251 ( 36.7 )
International 575 1,030 ( 44.2 ) 1,219 2,085 ( 41.5 )
Worldwide 1,653 2,885 ( 42.7 ) 3,278 5,336 ( 38.6 )
TREMFYA
U.S. 796 589 35.2 1,395 1,098 27.1
International 391 317 23.2 747 616 21.2
Worldwide 1,186 906 31.0 2,142 1,714 25.0
OTHER IMMUNOLOGY
U.S. 8 2 * 9 2 *
International 0 0 — 0 0 —
Worldwide 8 2 * 9 2 *
Neuroscience
U.S. 1,377 1,102 24.9 2,345 2,156 8.7
International 674 679 ( 0.8 ) 1,353 1,428 ( 5.2 )
Worldwide 2,051 1,782 15.1 3,698 3,585 3.2
CAPLYTA (2)
U.S. 211 — * 211 — *
International — — — — — —
Worldwide 211 — * 211 — *

22

Table of Contents
Fiscal Second Quarter Ended Fiscal Six Months Ended
(Dollars in Millions) June 29, 2025 June 30, 2024 Percent Change June 29, 2025 June 30, 2024 Percent Change
CONCERTA / methylphenidate
U.S. 24 34 ( 27.7 ) 62 75 ( 16.6 )
International 139 129 7.5 249 265 ( 6.0 )
Worldwide 164 163 0.2 312 340 ( 8.3 )
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
U.S. 732 784 ( 6.7 ) 1,357 1,549 ( 12.4 )
International 260 269 ( 3.5 ) 537 561 ( 4.2 )
Worldwide 992 1,054 ( 5.9 ) 1,895 2,110 ( 10.2 )
SPRAVATO
U.S. 366 226 61.1 642 417 53.7
International 50 44 12.8 93 78 18.1
Worldwide 414 271 53.3 734 496 48.1
OTHER NEUROSCIENCE
U.S. 45 57 ( 23.5 ) 73 115 ( 37.0 )
International 226 237 ( 4.7 ) 474 524 ( 9.5 )
Worldwide 270 294 ( 8.4 ) 547 639 ( 14.4 )
Pulmonary Hypertension
U.S. 799 743 7.6 1,543 1,509 2.3
International 314 296 5.8 595 579 2.6
Worldwide 1,113 1,039 7.1 2,138 2,088 2.4
OPSUMIT/OPSYNVI
U.S. 403 376 6.9 766 732 4.6
International 180 171 5.4 339 340 ( 0.3 )
Worldwide 582 548 6.4 1,104 1,072 3.0
UPTRAVI
U.S. 382 349 9.4 747 741 0.8
International 94 76 22.4 180 152 17.9
Worldwide 476 426 11.7 927 894 3.7
OTHER PULMONARY HYPERTENSION
U.S. 16 17 ( 12.4 ) 31 35 ( 12.6 )
International 40 49 ( 18.5 ) 77 88 ( 12.4 )
Worldwide 55 67 ( 16.9 ) 107 123 ( 12.5 )
Infectious Diseases
U.S. 320 334 ( 4.3 ) 635 658 ( 3.6 )
International 484 631 ( 23.4 ) 971 1,128 ( 13.9 )
Worldwide 803 965 ( 16.8 ) 1,605 1,786 ( 10.1 )
EDURANT / rilpivirine
U.S. 6 8 ( 25.4 ) 14 16 ( 13.6 )
International 354 288 23.0 704 603 16.7
Worldwide 360 297 21.6 718 620 15.9

Form 10-Q 23

Table of Contents
Fiscal Second Quarter Ended Fiscal Six Months Ended
(Dollars in Millions) June 29, 2025 June 30, 2024 Percent Change June 29, 2025 June 30, 2024 Percent Change
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
U.S. 312 321 ( 3.0 ) 617 635 ( 2.9 )
International 85 117 ( 27.0 ) 183 221 ( 17.2 )
Worldwide 396 438 ( 9.4 ) 799 856 ( 6.6 )
OTHER INFECTIOUS DISEASES
U.S. 2 5 ( 51.8 ) 4 7 ( 37.4 )
International 45 227 ( 80.5 ) 84 304 ( 72.5 )
Worldwide 47 233 ( 79.8 ) 88 311 ( 71.7 )
Cardiovascular / Metabolism / Other
U.S. 776 717 8.2 1,631 1,348 21.0
International 154 176 ( 12.3 ) 312 373 ( 16.2 )
Worldwide 930 892 4.2 1,943 1,721 12.9
XARELTO
U.S. 621 587 5.6 1,311 1,105 18.6
International — — — — — —
Worldwide 621 587 5.6 1,311 1,105 18.6
OTHER
U.S. 155 129 20.0 320 243 31.6
International 154 176 ( 12.3 ) 312 373 ( 16.2 )
Worldwide 309 305 1.4 632 616 2.7
TOTAL INNOVATIVE MEDICINE
U.S. 9,161 8,510 7.6 17,253 16,122 7.0
International 6,041 5,980 1.0 11,822 11,930 ( 0.9 )
Worldwide 15,202 14,490 4.9 29,075 28,052 3.6
MEDTECH
Cardiovascular
U.S. 1,364 1,119 21.9 2,625 2,144 22.4
International 948 753 25.9 1,790 1,534 16.7
Worldwide 2,313 1,873 23.5 4,416 3,679 20.0
ELECTROPHYSIOLOGY
U.S. 741 705 5.1 1,425 1,397 2.0
International 728 618 17.8 1,366 1,270 7.6
Worldwide 1,468 1,323 11.0 2,791 2,667 4.7
ABIOMED
U.S. 360 309 16.6 699 612 14.2
International 89 72 25.0 170 139 22.4
Worldwide 448 379 18.2 868 750 15.7
SHOCKWAVE (3)
U.S. 233 77 * 439 77 *
International 58 0 * 110 0 *
Worldwide 292 77 * 550 77 *

24

Table of Contents
Fiscal Second Quarter Ended Fiscal Six Months Ended
(Dollars in Millions) June 29, 2025 June 30, 2024 Percent Change June 29, 2025 June 30, 2024 Percent Change
OTHER CARDIOVASCULAR
U.S. 31 29 5.4 63 59 6.3
International 72 64 13.4 144 126 14.2
Worldwide 104 93 10.8 207 185 11.7
Orthopaedics
U.S. 1,420 1,422 ( 0.2 ) 2,804 2,870 ( 2.3 )
International 885 890 ( 0.5 ) 1,742 1,782 ( 2.2 )
Worldwide 2,305 2,312 ( 0.3 ) 4,546 4,652 ( 2.3 )
HIPS
U.S. 271 265 2.1 534 535 ( 0.2 )
International 150 152 ( 1.0 ) 296 304 ( 2.5 )
Worldwide 421 417 1.0 830 839 ( 1.1 )
KNEES
U.S. 226 230 ( 1.9 ) 457 472 ( 3.1 )
International 164 163 0.0 322 323 ( 0.5 )
Worldwide 389 394 ( 1.1 ) 778 795 ( 2.0 )
TRAUMA
U.S. 501 498 0.7 1,003 1,002 0.1
International 267 260 2.2 537 521 2.9
Worldwide 768 759 1.2 1,540 1,524 1.1
SPINE, SPORTS & OTHER
U.S. 422 430 ( 1.7 ) 810 862 ( 6.0 )
International 305 314 ( 2.7 ) 588 634 ( 7.2 )
Worldwide 727 743 ( 2.1 ) 1,398 1,495 ( 6.5 )
Surgery
U.S. 1,043 995 4.8 2,045 1,982 3.2
International 1,512 1,493 1.3 2,906 2,922 ( 0.5 )
Worldwide 2,555 2,488 2.7 4,951 4,904 1.0
ADVANCED
U.S. 477 466 2.2 934 912 2.4
International 687 675 1.9 1,303 1,316 ( 1.0 )
Worldwide 1,164 1,141 2.0 2,237 2,228 0.4
GENERAL
U.S. 567 528 7.2 1,111 1,070 3.8
International 825 818 0.9 1,603 1,606 ( 0.1 )
Worldwide 1,391 1,346 3.3 2,714 2,676 1.4
Vision
U.S. 557 523 6.5 1,123 1,070 4.9
International 813 763 6.5 1,526 1,473 3.6
Worldwide 1,369 1,285 6.5 2,648 2,543 4.1

Form 10-Q 25

Table of Contents
Fiscal Second Quarter Ended Fiscal Six Months Ended
(Dollars in Millions) June 29, 2025 June 30, 2024 Percent Change June 29, 2025 June 30, 2024 Percent Change
CONTACT LENSES / OTHER
U.S. 429 409 4.8 881 847 3.9
International 536 509 5.4 1,003 981 2.3
Worldwide 965 918 5.1 1,884 1,828 3.1
SURGICAL
U.S. 128 113 12.6 242 223 8.5
International 277 254 8.8 523 492 6.2
Worldwide 403 367 9.9 764 715 6.9
TOTAL MEDTECH
U.S. 4,383 4,059 8.0 8,596 8,067 6.6
International 4,158 3,898 6.7 7,965 7,711 3.3
Worldwide 8,541 7,957 7.3 16,561 15,778 5.0
WORLDWIDE
U.S. 13,544 12,569 7.8 25,849 24,189 6.9
International 10,199 9,878 3.2 19,787 19,641 0.7
Worldwide $ 23,743 22,447 5.8 % $ 45,636 43,830 4.1 %

*    Percentage greater than 100% or not meaningful
(1)
Includes the sales of RYBREVANT and RYBREVANT + LAZCLUZE
(2)
Acquired with the Intra-Cellular Therapies acquisition on April 2, 2025

(3)
Acquired on May 31, 2024
26

Table of Contents
Segment income before tax
Fiscal Second Quarter Ended
(Dollars in Millions) June 29, 2025 June 30, 2024
Innovative Medicine (1) MedTech (2) Total Innovative Medicine (1) MedTech (2) Total
Sales to customers $ 15,202 8,541 14,490 7,957
Cost of products sold 3,978 3,638 3,603 3,248
Selling, marketing and administrative 2,789 2,862 2,665 2,671
Research and development expense 2,869 647 2,722 718
Other segment items (3) 14 190 41 231
Segment income before tax $ 5,552 1,204 6,756 5,459 1,089 6,548
(Income)/Expense not allocated to segments (4) 265 800
Earnings before provision for taxes on income $ 6,491 $ 5,748
Fiscal Six Months Ended
Sales to customers $ 29,075 16,561 28,052 15,778
Cost of products sold 7,998 6,964 6,973 6,368
Selling, marketing and administrative 5,050 5,518 5,103 5,253
Research and development expense 5,417 1,324 5,618 1,364
Other segment items (3) ( 152 ) 130 ( 70 ) 184
Segment income before tax $ 10,762 2,625 13,387 10,428 2,609 13,037
(Income)/Expense not allocated to segments (4) ( 6,735 ) 3,575
Earnings before provision for taxes on income $ 20,122 $ 9,462

(1)
Innovative Medicine includes:
•
Intangible amortization expense of $
0.8
 billion and $
0.7
 billion in the fiscal second quarter of 2025 and 2024, respectively.
Intangible amortization expense of $
1.4
 billion in both the fiscal six months of 2025 and 2024.
•
Acquisition and integration related expense of $
0.2
 billion in both the fiscal second quarter of 2025 and fiscal six months of 2025, primarily related to the Intra-Cellular acquisition.
•
An In-process research and development impairment of $
0.2
 billion in the fiscal second quarter and fiscal six months of 2024 associated with the M710 (biosimilar) asset acquired from Momenta in 2020.
•
Restructuring income of $
0.1
 billion in the fiscal second quarter of 2024 and a restructuring related charge of $
0.1
 billion in the fiscal six months of 2024.
(2)    
MedTech includes:
•
Intangible amortization expense of $
0.5
 billion and $
0.4
 billion in the fiscal second quarter of 2025 and 2024, respectively.
Intangible amortization expense of $
1.0
 billion and $
0.8
 billion in the fiscal six months of 2025 and 2024, respectively.
•
Acquisition, integration and divestiture related net expense of $
0.1
 billion in the fiscal six months of 2025. Acquisition and integration related expense of $
0.4
 billion and $
0.5
 billion, in the fiscal second quarter and fiscal six months of 2024, respectively, primarily driven by the Abiomed and Shockwave acquisitions.
•
A restructuring related charge of $
0.1
 billion in both the fiscal second quarter and fiscal six months of 2025 and 2024. Refer to Note 12 for additional details.
(3)
    
Other segment expenses for each reportable segment include charges related to other income and expense, restructuring activities and impairment charges related to in-process research and development.
(4)

Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal six months of 2025 includes the reversal of approximately $
7.0
 billion, a significant portion of the previously accrued talc reserve. The fiscal second quarter and fiscal six months of 2024 includes charges for talc matters of $
0.3
 billion and $
3.0
 billion, respectively. For additional details related to talc refer to Note 11 to the Consolidated Financial Statements. The fiscal second quarter and six months of 2024 includes a loss of approximately $
0.4
 billion related to the debt to equity exchange of the Company's remaining shares of Kenvue Common Stock.

Form 10-Q 27

Table of Contents
Identifiable Assets
(Dollars in Millions) June 29, 2025 December 29, 2024
Innovative Medicine $ 75,487 57,070
MedTech 86,745 84,322
Total 162,232 141,392
General corporate (1) 31,157 38,712
Worldwide total $ 193,389 180,104

(1)
General corporate includes cash, cash equivalents, marketable securities and other corporate assets.
Additions to Property, Plant & Equipment Depreciation and Amortization
(Dollars in Millions) June 29, 2025 June 30, 2024 June 29, 2025 June 30, 2024
Innovative Medicine $ 687 553 $ 1,925 1,861
MedTech 1,071 1,074 1,678 1,552
Segments total 1,758 1,627 3,603 3,413
General corporate 80 156 112 184
Worldwide total $ 1,838 1,783 $ 3,715 3,597

Sales by geographic area
Fiscal Second Quarter Ended Fiscal Six Months Ended
(Dollars in Millions) June 29, 2025 June 30, 2024 Percent Change June 29, 2025 June 30, 2024 Percent Change
United States $ 13,544 12,569 7.8 % $ 25,849 24,189 6.9 %
Europe 5,387 5,214 3.3 10,497 10,377 1.1
Western Hemisphere, excluding U.S. 1,206 1,212 ( 0.5 ) 2,373 2,406 ( 1.3 )
Asia-Pacific, Africa 3,606 3,452 4.4 6,917 6,858 0.9
Total $ 23,743 22,447 5.8 % $ 45,636 43,830 4.1 %

28

Table of Contents
Note 10 —
Acquisitions and divestitures

Business combinations
2025 Transactions
On April 2, 2025, the Company completed the acquisition of Intra-Cellular Therapies, Inc. (Intra-Cellular), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders. This acquisition advances the Company’s industry-leading portfolio in mental health with the addition of CAPLYTA (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive therapy and monotherapy and is also approved for the treatment of schizophrenia in adults. Further, an sNDA has been submitted to the U.S. FDA for CAPLYTA as adjunctive treatment for major depressive disorder. This acquisition also includes a promising clinical-stage pipeline with best-in-class potential in generalized anxiety disorder and Alzheimer’s disease-related psychosis and agitation.
The Company acquired all the outstanding shares of Intra-Cellular’s common stock for $
132.00
per share in an all-cash merger transaction for total consideration transferred of $
14.5
 billion. The acquisition was accounted for as a business combination and the results of operations and goodwill are included in the Innovative Medicine segment as of the acquisition date. In addition, acquisition-related costs before tax incurred during the fiscal six months of 2025 were $
0.2
 billion, of which $
0.1
 billion related to post-closing compensation expense due to the acceleration of equity awards and were recorded to Other (income) expense, net.
The following table summarizes the preliminary fair value of assets acquired and liabilities assumed as of the acquisition date and is based on the best estimate of management, which is subject to change within the measurement period.
(Dollars in Billions) April 2, 2025
Assets acquired:
Cash and cash equivalents $ 0.2
Marketable securities 0.6
Other current & non-current assets 0.3
Amortizable intangible asset (1) 5.2
Acquired in-process research and development (1) 8.3
Goodwill (2) 2.9
Total assets acquired $ 17.5
Liabilities assumed:
Deferred taxes $ 2.8
Other current & non-current liabilities 0.2
Total liabilities assumed $ 3.0
Total assets acquired and liabilities assumed $ 14.5

(1)
The estimated fair values of the intangible assets acquired were determined using the multi-period excess earnings method. The amortizable intangible asset relates to the currently marketed product, Caplyta, which has an estimated useful life of
8
years. The acquired in-process research and development includes
two
assets, one related to certain unapproved indications of lumateperone and another related to a compound being studied to treat psychosis and agitation in patients with Alzheimer’s disease and generalized anxiety disorder. The fair value of the in-process research and development assets were calculated assuming a discount rate of
11.5
% and
12.5
%, respectively. Additionally, the cash flow projections assumed a probability of success factor of
95
% and approximately
34
-
50
% (depending on indication being studied), respectively.
(2)
Goodwill is primarily attributable to intangible assets that did not qualify for separate recognition and future projects or products currently unidentified. Goodwill is not expected to be deductible for tax purposes.
2024 Transactions
On June 20, 2024, the Company completed the acquisition of Proteologix, Inc., a privately held biotechnology company focused on bispecific antibodies for immune-mediated diseases, in an all-cash merger transaction for total consideration of $
0.8
 billion net of cash acquired, with potential for an additional milestone payment. The results of operations were included in the Innovative Medicine segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $
1.2
 billion, primarily non-amortizable intangible assets, inclusive of purchased IPR&D, for $
0.9
 billion, goodwill for $
0.3
 billion, and liabilities
Form 10-Q 29

Table of Contents
assumed of $
0.3
 billion, including $
0.1
 billion of contingent consideration. The goodwill is not deductible for tax purposes. Acquisition related costs before tax for the fiscal six months of 2025 are
not
material.
On May 31, 2024, the Company acquired all the outstanding shares of Shockwave Medical Inc. (SWAV), a leading, first-to-market provider of innovative intravascular lithotripsy (IVL) technology for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD), in an all-cash merger transaction for total consideration of $
12.6
 billion, ($
11.5
 billion, net of cash acquired). The results of operations were included in the MedTech segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $
14.4
 billion primarily amortizable intangible assets of $
5.3
 billion, purchased IPR&D of $
0.6
 billion, goodwill for $
7.6
 billion, $
0.5
 billion of inventory and $
0.4
 billion of other assets, and liabilities assumed of $
2.9
 billion. The goodwill is not deductible for tax purposes. Acquisition related costs before tax for the fiscal six months of 2025 are not material.
On March 7, 2024, the Company completed the acquisition of Ambrx Biopharma, Inc., (Ambrx), a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total consideration of approximately $
1.8
 billion net of cash acquired. The results of operations were included in the Innovative Medicine segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $
2.3
 billion, primarily non-amortizable intangible assets, inclusive of purchased IPR&D, for $
1.9
 billion, goodwill for $
0.3
 billion and liabilities assumed of $
0.5
 billion. The goodwill is not deductible for tax purposes. Acquisition related costs before tax for the fiscal six months of 2025 are
not
material.
Asset acquisitions
There were no material asset acquisitions in the fiscal six months of 2025 or 2024.
Divestitures
There were no material divestitures in the fiscal six months of 2025.
In the fiscal second quarter of 2024, the Company completed the divestiture of Acclarent resulting in approximately $
0.3
 billion in proceeds. In the fiscal first quarter of 2024, the Company completed the divestiture of Ponvory outside of the U.S. resulting in approximately $
0.2
 billion in proceeds.
30

Table of Contents
Note 11 —
Legal proceedings
Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.
The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of June 29, 2025, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.
In the Company’s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company’s balance sheet, is not expected to have a material adverse effect on the Company’s financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company’s results of operations and cash flows for that period.
Matters concerning talc
A significant number of personal injury claims alleging that talc causes cancer have been asserted against the Company and its affiliates arising out of the use of body powders containing talc, primarily JOHNSON’S Baby Powder.
In talc cases that have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $
4.7
 billion in Ingham v. Johnson & Johnson, et al., No. ED 207476 (Mo. App.), reducing the overall award to $
2.1
 billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied, and in June 2021, a petition for certiorari, seeking a review of the Ingham decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $
2.5
 billion. The facts and circumstances, including the terms of the award, were unique to the Ingham decision and not representative of other claims brought against the Company. The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Company’s confidence in the safety of its talc products, in certain circumstances the Company has settled cases.
In an effort to expeditiously resolve the litigation for the overwhelming majority of claimants, beginning in October 2021, Johnson & Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring, through which Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtor’s direct parent, Johnson & Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCI’s assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers’ compensation statute or act (the Talc-Related Liabilities).
Following the 2021 Corporate Restructuring, Debtor and the Company attempted to achieve a full and comprehensive resolution of the Talc-Related Liabilities. Debtor filed voluntary petitions for Bankruptcy pursuant to Chapter 11 of the Bankruptcy Code in October 2021 and again in April 2023; both petitions were dismissed.
In October 2023, the Company stated that it was pursuing the following four parallel and alternative pathways to achieve a comprehensive and final resolution of the talc claims: (i) the appeal of the LTL 2 dismissal decision; (ii) pursuing a consensual “prepackaged” bankruptcy case, as “strongly encouraged” by the Bankruptcy Court in its dismissal decision; (iii) aggressively litigating the talc claims in the tort system; and (iv) pursuing affirmative claims against experts for false and defamatory narratives
Form 10-Q 31

Table of Contents
regarding the Company’s talc powder products. In December 2023, LTL changed its state of formation to Texas and its name to LLT Management LLC (LLT).
In May 2024, the Company commenced a
three-month
solicitation period of its proposed consensual “prepackaged” Chapter 11 bankruptcy plan (the Proposed Plan) for the comprehensive and final resolution of all current and future claims related to cosmetic talc in the United States, excluding claims related to mesothelioma or State consumer protection claims, in exchange for the payment by the Company of present value of approximately $
6.475
 billion payable over
25
years (nominal value of approximately $
8.0
 billion, discounted at a rate of
4.4
%). The claims encompassed by the Proposed Plan constituted
99.75
% of then-pending lawsuits against the Company relating to its talc powder products.
In August 2024, LLT engaged in a restructuring that resulted in the creation of three new Texas limited liability companies: (a) Red River Talc, LLC (Red River); (b) Pecos River Talc LLC (Pecos River); and (3) New Holdco (Texas) LLC. As a result of this restructuring, all claims related to ovarian and other gynecological cancers were separated and allocated to Red River, and mesothelioma, governmental unit and certain other claims were allocated to Pecos River.
While the Company had resolved
95
% of the mesothelioma lawsuits filed to date as of August 2024, cases continue to be filed. Trials have commenced in various state courts.
In September 2024, while reiterating the Company's continued confidence in the safety of its talc products, Red River filed a voluntary petition with the United States Bankruptcy Court for the Southern District of Texas, seeking relief under Chapter 11 of the Bankruptcy Code (the Red River Bankruptcy Case), in furtherance of the Company's consensual "prepackaged" Proposed Plan. Shortly thereafter, as a consequence of this filing, the Company withdrew its appeal of the LTL 2 dismissal decision.
To account for the contemplated comprehensive resolution through the Proposed Plan, the Company recorded a cumulative incremental charge of approximately $
5.0
 billion during fiscal year 2024. As of the end of fiscal year 2024, the total present value of the reserve was approximately $
11.6
 billion (or nominal value of approximately $
13.5
 billion).
On March 31, 2025, the Texas Bankruptcy Court issued an order dismissing the case (the Texas dismissal) and, as a result, the Company reversed substantially all, or approximately $
7
 billion, from amounts previously reserved for the bankruptcy resolution. As of the second quarter 2025, the total present value of the reserve is approximately $
4.0
 billion, comprising previously executed settlement agreements, litigation defense and other costs. Approximately one-third of the reserve is recorded as a current liability.
After the Texas dismissal, the Company announced it would not appeal the decision and returned to the tort system to litigate the talc claims and defend the safety of its products. Courts have begun to hold scheduling conferences and the Company is preparing to start bellwether trials in consolidated proceedings in the California JCCP in November 2025 and in the New Jersey MCL in January 2026.
In February 2019, the Company’s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition for relief under Chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy) seeking indemnification from the Company and rights to joint insurance proceeds.
In February 2021, Cyprus Mines Corporation (Cyprus), which had owned certain Imerys talc mines, filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code in the Delaware Bankruptcy Court and filed its Disclosure Statement and Plan (the Cyprus Plan) also asserting claims for indemnity against the Company arising out of personal injury claims.
In July 2024, the Company, Imerys, and Cyprus and certain of their affiliates (including their parent entities), and the tort claimants' committees and future claimants' representatives appointed in the Imerys debtors' and Cyprus debtors' respective Chapter 11 cases entered into a global settlement agreement (the Imerys Settlement Agreement) to resolve the parties ongoing disputes, including disputes raised in the Imerys and Cyprus bankruptcies. In October 2024, the Delaware Bankruptcy Court entered an order approving the Imerys Settlement Agreement (the Settlement Order).
Certain insurers have appealed the Settlement Order and sought a stay of the order pending appeal, which the Delaware Bankruptcy Court denied in January 2025. The insurers then sought a stay of the order in the District Court for the District of Delaware, which also was denied. The insurers then appealed the denial of their request for a stay of the order to the Third Circuit Court of Appeals. The briefing of the Settlement Order appeal in the Delaware District Court was completed in April 2025, and the appeal is pending a decision from the Court. The briefing in the Third Circuit appeal of the denial of the stay order is ongoing.
In January 2025, Imerys and Cyprus each filed a certification of voting results, indicating that their respective Chapter 11 plans had been accepted by each voting class of talc claimants. A joint confirmation hearing for the plans began in April 2025 but was continued, at the request of Imerys and Cyprus, after issues arose relating to treatment of foreign claims under their respective Chapter 11 plans.
32

Table of Contents
In February 2018, a securities class action lawsuit was filed against the Company and certain named officers in the United States District Court for the District of New Jersey, alleging that the Company violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON’S Baby Powder, and that purchasers of the Company’s shares suffered losses as a result. In April 2019, the Company moved to dismiss the complaint. In December 2019, the Court denied, in part, the motion to dismiss. In December 2023, the Court granted Plaintiff’s motion for class certification. In January 2024, Defendants filed a petition with the Third Circuit under Federal Rule of Civil Procedure 23(f) for permission to appeal the Court’s order granting class certification, and in February 2024, the Third Circuit granted Defendants' petition. In February 2024, fact discovery closed, the Court ordered the parties to mediate, and stayed the case pending mediation. In May 2024, the parties participated in an unsuccessful mediation. In June 2024, at the parties' request, the Court lifted the stay for certain limited discovery, but otherwise kept the stay in place pending a decision from the Third Circuit on the 23(f) petition. Briefing on the 23(f) petition was completed in September 2024, and in March 2025, the Third Circuit heard oral argument.
Matters concerning opioids
Beginning in 2014 and continuing to the present, the Company and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in close to
3,500
lawsuits related to the marketing of opioids, including DURAGESIC, NUCYNTA and NUCYNTA ER. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children born with Neonatal Abstinence Syndrome (NAS); hospitals; and health insurers/payors.
To date, the Company and JPI have litigated two of the cases to judgment and have prevailed in both, either at trial or on appeal.
In July 2021, the Company announced finalization of an agreement to settle the state and subdivision claims for up to $
5.0
 billion. Approximately
80
% of the all-in settlement was paid by the end of fiscal second quarter 2025. A few government entities opted out of the settlement. In September 2024, the Company reached an agreement to resolve the hospital cases.
The Company and JPI continue to defend the cases brought by the remaining government entity litigants as well as the cases brought by private litigants. In total, there are under
27
remaining opioid cases against the Company and JPI in various state courts,
290
remaining cases in the Ohio multi-district litigation (MDL), and
2
additional cases in other federal courts.
In addition, the Province of British Columbia filed suit against the Company and its Canadian affiliate Janssen Inc., and many other industry members, in Canada. That action was certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada in January 2025. The defendants, including the Company, filed appeals from the certification order in late February 2025. Additional proposed class actions have been filed in Canada against the Company and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. The proposed class action in Quebec on behalf of residents diagnosed with opioid use disorder was authorized to proceed against Janssen Inc. and other industry members in April 2024; and leave to appeal was denied in October 2024.
Starting in November 2019, a series of shareholder derivative complaints were filed against the Company as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that the Company has suffered damages as a result of those alleged breaches. As of September 2024, all the complaints had been dismissed, and all appeals exhausted.
Product liability
The Company and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25, Contingencies. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.
The table below contains the most significant of these cases and provides the approximate number of plaintiffs in the United States with direct claims in pending lawsuits regarding injuries allegedly due to the relevant product or product category as of June 29, 2025
Form 10-Q 33

Table of Contents
Product or product category Number of plaintiffs
Body powders containing talc, primarily JOHNSON’S Baby Powder 70,030
DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System 40
PINNACLE Acetabular Cup System 860
Pelvic meshes 5,350
ETHICON PHYSIOMESH Flexible Composite Mesh 120
ELMIRON 920

The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. There may be additional claims that have not yet been filed.
MedTech
DePuy ASR XL Acetabular System and ASR Hip Resurfacing System
In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Ireland, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States. This settlement program has resolved more than
10,000
claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.
DePuy PINNACLE Acetabular Cup System
Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and the Company (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.
Ethicon Pelvic Mesh
Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company arising out of Ethicon’s pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company’s accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicon’s pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, and Ireland, and class actions in Israel, Australia, Canada and South Africa. The vast majority of these actions are now resolved. The Company has established accruals with respect to product liability litigation associated with Ethicon’s pelvic mesh products.
Ethicon Physiomesh
Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this
34

Table of Contents
hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately
3,600
Physiomesh cases (covering approximately
4,300
plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes
3,729
cases in the MDL and MCL. Other than a small number of cases still pending in the MDL, all Physiomesh matters in the United States have been resolved or are undergoing formal review for purposes of settlement.
Claims have also been filed against Ethicon and the Company alleging personal injuries arising from the PROCEED Mesh and PROCEED Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States.
Ethicon and the Company also have been subject to claims for personal injuries arising from the PROLENE Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States.
In October 2022, an agreement in principle, subject to various conditions, was reached to settle the majority of the pending cases involving Proceed, Proceed Ventral Patch, Prolene Hernia System and related multi-layered mesh products, as well as a number of unfiled claims. All litigation activities in the two New Jersey MCLs are stayed pending effectuation of the proposed settlement. Future cases that are filed in the New Jersey MCLs will be subject to docket control orders requiring early expert reports and discovery requirements.
The Company has established accruals with respect to product liability litigation associated with Ethicon Physiomesh Flexible Composite Mesh, PROCEED Mesh and PROCEED Ventral Patch, and PROLENE Polypropylene Hernia System products.
Innovative Medicine
ELMIRON
Claims for personal injury have been made against a number of Johnson & Johnson companies, including Janssen Pharmaceuticals, Inc. and the Company, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey (MDL). In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well as the Court of Common Pleas in Philadelphia, which have been coordinated and granted mass tort designation. In addition, three class action lawsuits have been filed in Canada. The Company continues to defend ELMIRON product liability lawsuits and continues to evaluate potential costs related to those claims. All U.S. based ELMIRON matters have been resolved or are undergoing formal review for purposes of settlement. The Company has established accruals for defense and indemnity costs associated with ELMIRON related product liability litigation.
Intellectual property
Certain subsidiaries of the Company are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the scope and/or validity of patents that relate to various products and allegations that certain of the Company’s products infringe the intellectual property rights of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset.
Innovative Medicine - litigation against filers of abbreviated new drug applications (ANDAs)
The Company’s subsidiaries have brought lawsuits against generic companies that have filed ANDAs with the U.S. FDA (or similar lawsuits outside of the United States) seeking to market generic versions of products sold by various subsidiaries of the Company prior to expiration of the applicable patents covering those products. These lawsuits typically include allegations of non-
Form 10-Q 35

Table of Contents
infringement and/or invalidity of patents listed in FDA’s publication “Approved Drug Products with Therapeutic Equivalence Evaluations” (commonly known as the Orange Book). In each of these lawsuits, the Company’s subsidiaries are seeking an order enjoining the defendant from marketing a generic version of a product before the expiration of the relevant patents (Orange Book Listed Patents). In the event the Company’s subsidiaries are not successful in an action, or any automatic statutory stay expires before the court rulings are obtained, the generic companies involved would have the ability, upon regulatory approval, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Company’s subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents.
The Inter Partes Review (IPR) process with the United States Patent and Trademark Office (USPTO), created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits to challenge the applicable patents.
XARELTO
Beginning in March 2021, Janssen Pharmaceuticals, Inc., Bayer Pharma AG, Bayer AG and Bayer Intellectual Property GmbH filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of XARELTO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Dr. Reddy’s Laboratories, Inc.; Dr. Reddy’s Laboratories, Ltd.; Lupin Limited; Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd.; Taro Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mankind Pharma Limited; Apotex Inc.; Apotex Corp.; Cipla Ltd.; Cipla USA Inc.; and InvaGen Pharmaceuticals, Inc. The following U.S. patents are included in one or more cases: 9,539,218 and 10,828,310.
U.S. Patent No. 10,828,310 was also under consideration by the USPTO in an IPR proceeding. In July 2023, the USPTO issued a final written decision finding the claims of the patent invalid. In September 2023, Bayer Pharma AG filed an appeal to the U.S. Court of Appeals for the Federal Circuit. Oral argument was heard in May 2025.
INVEGA SUSTENNA
Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Teva Pharmaceuticals USA, Inc.; Mylan Laboratories Limited; Pharmascience Inc.; Mallinckrodt PLC; Specgx LLC; Tolmar, Inc.; Accord Healthcare, Inc.; Qilu Pharmaceutical Co. Ltd.; and Qilu Pharma Inc. The following U.S. patent is included in one or more cases: 9,439,906. In October 2020, the district court issued a decision in the case against Teva Pharmaceuticals USA, Inc., finding that United States Patent No. 9,439,906 is not invalid. Teva previously stipulated to infringement. Teva appealed the decision, and, in April 2024, the United States Court of Appeals for the Federal Circuit vacated and remanded the case to the district court for further proceedings. In November 2024, the district court issued its decision on remand, finding that United States Patent No. 9,439,906 is not invalid. Teva appealed to the Court of Appeals for the Federal Circuit, and oral argument took place in April 2025. In July 2025, the Federal Circuit affirmed the district court ruling of no invalidity. The Mylan case was consolidated with the Teva case for purposes of appeal and the July ruling applies to Mylan. In February 2024, the district court issued a decision in the case against Tolmar Inc. finding that United States Patent No. 9,439,906 is not invalid. Tolmar previously stipulated to infringement. Tolmar has appealed the decision.
Beginning in February 2018, Janssen Inc. and Janssen Pharmaceutica NV initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who have filed ANDSs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the listed patent. The following entities are named defendants: Pharmascience Inc. and Apotex Inc. The following Canadian patent is included in one or more cases: 2,655,335. In June 2024, the Supreme Court dismissed the Apotex case. In September 2024, the Supreme Court granted Pharmascience's motion to appeal the Federal Court's decision that the 2,655,335 Patent is not invalid.
INVEGA TRINZA
Beginning in September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research & Development, LLC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA TRINZA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Mylan Laboratories Limited; Mylan Pharmaceuticals Inc.; and Mylan Institutional LLC. The following U.S. patent is included in one or more cases: 10,143,693. In May 2023, the District Court issued a decision finding that Mylan’s proposed generic product infringes the asserted patent and that the patent is not invalid. Mylan appealed the decision, and in March 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the district court's decision. In May 2025, Mylan filed a petition for panel
36

Table of Contents
rehearing or rehearing en banc with the U.S. Court of Appeals for the Federal Circuit. In July 2025, the court denied Mylan's petition.
ERLEADA
In January 2025, Aragon Pharmaceuticals, Inc., Janssen Inc., (collectively, Janssen Inc.) and Sloan-Kettering Institute for Cancer Research (SKI) initiated Statements of Claims under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in response to Sandoz’s filing of an ANDS seeking approval to market a generic version of ERLEADA before the expiration of CA Patent Nos. 3,008,345 (the ’345 patent), 2,875,767 (the ’767 patent), 2,885,415 (the ’415 patent), and 3,128,331 (the ’331 patent). Janssen Inc. and SKI are seeking an order enjoining Sandoz from marketing a generic version of ERLEADA before the expiration of the relevant patents.
Beginning in April 2025, Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc., The Regents of the University of California, and Sloan-Kettering Institute for Cancer Research variously initiated patent infringement lawsuits in U.S. District Court for the District of New Jersey against generic manufactures who have filed ANDAs seeking approval to market generic versions of ERLEADA before the expiration of certain Orange Book listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; Hetero Labs Limited Unit V; and Hetero USA, Inc. The following U.S. patents are included in one or more cases: 8,445,507; 8,802,689; 9,338,159; 9,987,261; 9,481,663; 9,884,054; RE49,353; 10,849,888; 10,702,508; and 11,963,952.
SPRAVATO
Beginning in May 2023, Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SPRAVATO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sandoz Inc.; Hikma Pharmaceuticals Inc. USA; Hikma Pharmaceuticals PLC; and Alkem Laboratories Ltd. The following U.S. patents are included in one or more cases: 10,869,844; 11,173,134; 11,311,500; and 11,446,260.
INVOKANA
Beginning in January 2024, Janssen Inc. and Mitsubishi Tanabe Pharma Corporation initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who filed ANDSs seeking approval to market generic versions of INVOKANA before expiration of the listed patents. The following entities are named defendants Jamp Pharma Corporation (Jamp) and Apotex Inc. (Apotex). The following Canadian patents are included in one or more cases 2,534,024 and 2,671,357. The Company entered into confidential settlement agreements with Jamp, in April 2025, and with Apotex, in July 2025.
CAPLYTA

Beginning in March 2024, Intra-Cellular Therapies, Inc. (Intra-Cellular) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against generic manufactures who have filed ANDAs seeking approval to market generic versions of CAPLYTA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Alkem Laboratories Ltd., Dr. Reddy’s Laboratories Inc., Dr. Reddy’s Laboratories Ltd., Hetero USA, Inc., Hetero Labs Ltd. Unit-V, Hetero Labs Ltd., MSN Laboratories Private Ltd., Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Ltd. The following U.S. Patents are included in one or more cases: US RE 48,825; RE 48,839; 8,648,077; 9,168,258; 9,199,995; 9,616,061; 9,956,227; 10,117,867; 10,464,938; 10,960,009; 11,026,951; 11,753,419; 11,980,617; 12,070,459; 12,090,155; 12,122,792; and 12,128,043. In July 2025, Intra-Cellular, Hetero USA, Inc., Hetero Labs Ltd. Unit-V, and Hetero Labs Ltd. entered into a confidential settlement agreement.
MedTech
In March 2016, Abiomed, Inc. filed a declaratory judgment action against Maquet Cardiovascular LLC (Maquet) in the U.S. District Court for the District of Massachusetts seeking a declaration that certain Impella products do not infringe Maquet patents, including U.S. Patent Nos. 7,022,100 (’100 patent); 8,888,728; and 9,327,068. Maquet counterclaimed for infringement of those patents against Abiomed, Inc., Abiomed Europe GmbH, and Abiomed R&D, Inc. (collectively, Abiomed), and later added claims for infringement of U.S. Patent Nos. 9,545,468; 9,561,314; and 9,597,437. After claim construction, Maquet alleged infringement of only the ’100 patent. In September 2021, the court granted Abiomed’s motion for summary judgment of non-infringement of the ’100 patent, and in September 2023, the district court entered final judgment in favor of Abiomed on all patents-in-suit. Maquet appealed.
In November 2017, Maquet Cardiovascular LLC filed suit against Abiomed, Inc., Abiomed R&D, Inc., and Abiomed Europe GmbH (collectively, Abiomed) in the U.S. District Court for the District of Massachusetts, alleging that certain Impella products infringe U.S. Patent No. 9,789,238 (’238 patent). Maquet subsequently added U.S. Patent No. 10,238,783 (’783 patent). After claim construction, the court entered a stipulated judgment of non-infringement of both patents. Maquet appealed. On March 21, 2025,
Form 10-Q 37

Table of Contents
the U.S. Court of Appeals for the Federal Circuit left undisturbed the judgment on non-infringement of the ’238 patent, vacated the judgment regarding the ’783 patent, and remanded the case to the District Court for further proceedings on the ’783 patent.
Government proceedings
Like other companies in the pharmaceutical and medical technologies industries, the Company and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.
MedTech
In July 2023, the DOJ issued Civil Investigative Demands to the Company, Johnson & Johnson Surgical Vision, Inc., and Johnson & Johnson Vision Care, Inc. (collectively, J&J Vision) in connection with a civil investigation under the False Claims Act relating to free or discounted intraocular lenses and equipment used in eye surgery, such as phacoemulsification and laser systems. J&J Vision has provided documents and information responsive to the Civil Investigative Demands and is continuing to cooperate with the DOJ regarding its inquiry.
Innovative Medicine
In July 2016, the Company and Janssen Products, LP were served with a qui tam complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. Daubert motions were granted in part and denied in part in January 2022, and trial commenced in May 2024. On June 13, 2024, a jury found no liability regarding the anti-kickback violations but found liability for a portion of the off-label promotion claims. The Company is pursuing post-trial briefing challenging the verdict on the off-label claims. On March 28, 2025, the Court granted in part and denied in part Janssen’s motions and the Company is appealing the verdict and judgments. The Company filed a notice of appeal with the Third Circuit on April 29, 2025. Briefing is ongoing.
In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a qui tam False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the qui tam lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway.
General litigation
The Company or its subsidiaries are also parties to various proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the Company’s agreement to implement remediation activities at designated hazardous waste sites or to reimburse the government or third parties for the costs they have incurred in performing remediation at such sites.
In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson & Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Court’s decision. In June 2023, defendants filed a petition for a writ of certiorari to the United States Supreme Court. In June 2024, the Supreme Court vacated the D.C. Circuit's decision and remanded the case to the D.C. Circuit. Oral argument was held in November 2024.
In February 2024, a putative class action was filed against the Company and the Pension & Benefits Committee of Johnson & Johnson (Committee) in United States District Court for the District of New Jersey. The complaint alleges that defendants breached fiduciary duties under the Employee Retirement Income Security Act (ERISA) by allegedly mismanaging the Company’s prescription-drug benefits program. The complaint seeks damages and other relief. In January 2025, the Court granted in part and
38

Table of Contents
denied in part defendants’ motion to dismiss, with leave to replead. In March 2025, plaintiffs filed a second amended complaint. In April 2025, defendants filed a motion to dismiss plaintiffs' fiduciary duty claims.
MedTech
In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against the Company, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon’s acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants’ motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial occurred in January 2024. In September 2024, the court found liability with respect to certain claims and no liability with respect to other claims. The Company has appealed the decision.
In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc (BWI) in the United States District Court for the Central District of California. The complaint alleges that certain of BWI's business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. In May 2025, a jury returned its verdict in favor of Innovative Health. Innovative Health is seeking a permanent injunction. BWI intends to appeal once the judgment is final.
Innovative Medicine
In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc. and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the U.S. Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. In September 2024, the district court granted plaintiff's motion for class certification. Trial is scheduled for March 2026.
In December 2023, a putative class action lawsuit was filed against the Company and Janssen Biotech Inc. (collectively Janssen) in the United States District Court for the Eastern District of Virginia. The complaint alleges that Janssen violated federal and state antitrust laws and other state laws by delaying biosimilar competition with STELARA through Janssen's enforcement of patent rights covering STELARA. The complaint seeks damages and other relief. In February 2024, plaintiffs filed an amended complaint, which Janssen moved to dismiss in March 2024. In August 2024, the court granted in part and denied in part Janssen's motion to dismiss.
In December 2018, Janssen Biotech, Inc., Janssen Oncology, Inc., Janssen Research & Development, LLC and Johnson & Johnson (collectively, Janssen) were served with a qui tam complaint on behalf of the United States, certain states, and the District of Columbia. The complaint alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA to the government in connection with direct sales and reimbursement programs. At this time, the federal and state governments have declined to intervene. In December 2021, the United States District Court for the District of New Jersey denied Janssen's motion to dismiss.

Form 10-Q 39

Table of Contents
Note 12 —
Restructuring
In fiscal 2025, the company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select sites across the network. Restructuring expenses of $
29
 million were recorded in the fiscal second quarter of 2025. The estimated costs of the total program are between $
0.9
 billion - $
1.0
 billion and is expected to be completed over the next
two years
.
In fiscal 2023, the Company initiated a restructuring program of its Orthopaedics franchise within its MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The pre-tax restructuring expense in the

fiscal second quarter and fiscal six months of 2025 primarily included costs related to asset impairments as well as market and product exits. The pre-tax restructuring expense in the fiscal second quarter and fiscal six months of 2024 primarily included market and product exits. Total project costs of approximately $
0.6
 billion have been recorded since the restructuring was announced. The estimated costs of the total program are between $
0.7
 billion - $
0.8
 billion and is expected to be substantially completed by the end of fiscal year 2025.
The following table summarizes the restructuring expenses for 2025 and 2024:
(Pre-tax Dollars in Millions) Q2 2025 Q2 2024 Q2 YTD 2025 Q2 YTD 2024
MedTech Segment Surgery franchise (1) $ 29 — 29 —
MedTech Segment Orthopaedics franchise (2) 50 52 105 79
Innovative Medicine Segment (3) — ( 63 ) — 81
Total Programs $ 79 ( 11 ) 134 160

(1)
Included in Restructuring on the Consolidated Statement of Earnings in the fiscal second quarter and fiscal six months of 2025.
(2)
Included $
35
 million in Restructuring and $
15
 million in Cost of products sold on the Consolidated Statement of Earnings in the fiscal second quarter of 2025. Included $
52
 million in Restructuring, $
23
 million in Cost of products sold and $
30
 million in Other (Income)/Expense on the Consolidated Statement of Earnings in the fiscal six months of 2025. Included $
50
 million in Restructuring and $
2
 million in Cost of products sold on the Consolidated Statement of Earnings in the fiscal second quarter of 2024. Included $
70
 million in Restructuring and $
9
 million in Cost of products sold on the Consolidated Statement of Earnings in the fiscal six months of 2024.
(3)
Included in Restructuring on the Consolidated Statement of Earnings. This program was completed in the fiscal fourth quarter of 2024.
Restructuring reserves as of June 29, 2025 and December 29, 2024 were insignificant.
40

Table of Contents
Item 2 — Management’s discussion and analysis of financial condition and results of operations
Results of operations
Sales to customers
Analysis of consolidated sales
For the fiscal six months of 2025, worldwide sales were $45.6 billion, a total increase of 4.1%, including an operational* increase of 4.4% as compared to 2024 fiscal six months sales of $43.8 billion. Currency fluctuations had a negative impact of 0.3% for the fiscal six months of 2025. In the fiscal six months of 2025, acquisitions and divestitures had net positive impact of 1.3% on worldwide operational sales growth. In the fiscal six months of 2025, the negative impact of the Stelara sales decline, due to biosimilar competition, on worldwide operational sales was approximately 5.9%.
Sales by U.S. companies were $25.8 billion in the fiscal six months of 2025, which represented an increase of 6.9% as compared to the prior year. In the fiscal six months of 2025, acquisitions and divestitures had net positive impact of 2.2% on U.S. operational sales growth. In the fiscal six months of 2025, the negative impact of the Stelara sales decline, due to biosimilar competition on U.S. operational sales was approximately 6.7%. Sales by international companies were $19.8 billion, which represented an increase of 0.7%, including an operational increase of 1.4%, partially offset by a negative currency impact of 0.7% as compared to the fiscal six months sales of 2024. In the fiscal six months of 2025, the net impact of acquisitions and divestitures on international operational sales growth was a positive 0.3%. In the fiscal six months of 2025, the negative impact of the Stelara sales decline, due to biosimilar competition, on international operational sales was approximately 5.0%.
In the fiscal six months of 2025, sales by companies in Europe achieved growth of 1.1%, which included an operational increase of 0.2% and a positive currency impact of 0.9%. Sales by companies in the Western Hemisphere, excluding the U.S., experienced a decline of 1.3%, which included an operational increase of 7.7% offset by negative currency impact of 9.0%. Sales by companies in the Asia-Pacific, Africa region achieved growth of 0.9%, including operational growth of 0.9% and a currency impact of 0.0%.
Fiscal six months 2025
sales by geographic region (in billions)
Fiscal six months 2025
sales by segment (in billions)
Note: values may have been rounded
*operational growth excludes the effect of translational currency
Form 10-Q 41

Table of Contents
For the fiscal second quarter of 2025, worldwide sales were $23.7 billion, a total increase of 5.8%, which included operational growth of 4.6% and a currency impact of 1.2% as compared to 2024 fiscal second quarter sales of $22.4 billion. In the fiscal second quarter of 2025, the net impact of acquisitions and divestitures on worldwide operational sales growth was a positive 1.6%. In the fiscal second quarter of 2025, the negative impact of the Stelara sales decline, due to biosimilar competition, on worldwide operational sales was approximately 7.1%.
Sales by U.S. companies were $13.5 billion in the fiscal second quarter of 2025, which represented an increase of 7.8% as compared to the prior year. In the fiscal second quarter of 2025, the net impact of acquisitions and divestitures on U.S. operational sales growth was a positive 2.8%. In the fiscal second quarter of 2025, the negative impact of the Stelara sales decline, due to biosimilar competition on U.S. operational sales was approximately 8.5%. Sales by international companies were $10.2 billion, a total increase of 3.2%, which included operational growth of 0.6% and a positive currency impact of 2.6%. In the fiscal second quarter of 2025, the net impact of acquisitions and divestitures on international operational sales growth was a positive 0.2%. In the fiscal second quarter of 2025, the negative impact of the Stelara sales decline, due to biosimilar competition, on international operational sales was approximately 5.4%.
In the fiscal second quarter of 2025, sales by companies in Europe achieved growth of 3.3%, which included an operational decline of 1.9% offset by a positive currency impact of 5.2%. Sales by companies in the Western Hemisphere, excluding the U.S., experienced a sales decline of 0.5%, which included operational growth of 6.2% offset by a negative currency impact of 6.7%. Sales by companies in the Asia-Pacific, Africa region achieved growth of 4.4%, which included operational growth of 2.4% and a positive currency impact of 2.0%.
Q2 2025
Sales by Geographic Region (in billions)
Q2 2025
Sales by Segment (in billions)
Note: values may have been rounded
42

Table of Contents
Analysis of sales by business segments
Innovative Medicine
Innovative Medicine segment sales in the fiscal six months of 2025 were $29.1 billion, an increase of 3.6% as compared to the same period a year ago, with an operational increase of 4.0% and a negative currency impact of 0.4%. U.S. Innovative Medicine sales increased 7.0% as compared to the same period a year ago. International Innovative Medicine sales decreased by 0.9%, including an operational decline of 0.1% and a negative currency impact of 0.8%. In the fiscal six months of 2025, the net impact of acquisitions and divestitures on the Innovative Medicine segment operational sales growth was a positive 0.7%, primarily related to CAPLYTA. In the fiscal six months of 2025, the negative impact of the STELARA sales decline, due to biosimilar competition, was an approximate 9.9%, 11.0% and 8.6% on worldwide, U.S. and international Innovative Medicine segment operational sales, respectively.
Major Innovative Medicine therapeutic area sales — Fiscal Six Months Ended
(Dollars in Millions) June 29, 2025 June 30, 2024 Total Change Operations Change Currency Change
Oncology $11,990 $9,904 21.1 % 21.3 % (0.2) %
CARVYKTI 808 343 * * *
DARZALEX 6,776 5,570 21.7 22.0 (0.3)
ERLEADA 1,679 1,425 17.8 17.9 (0.1)
IMBRUVICA 1,444 1,554 (7.0) (6.6) (0.4)
RYBREVANT/ LAZCLUZE (1) 320 116 * * *
TALVEY 192 127 52.0 52.4 (0.4)
TECVAYLI 317 268 18.2 18.7 (0.5)
ZYTIGA/ abiraterone acetate 270 346 (21.7) (21.9) 0.2
Other Oncology 182 156 16.4 16.8 (0.4)
Immunology 7,700 8,969 (14.1) (13.6) (0.5)
REMICADE 922 827 11.5 12.4 (0.9)
SIMPONI/ SIMPONI ARIA 1,349 1,091 23.7 25.1 (1.4)
STELARA 3,278 5,336 (38.6) (38.2) (0.4)
TREMFYA 2,142 1,714 25.0 25.4 (0.4)
Other Immunology 9 2 * * —
Neuroscience 3,698 3,585 3.2 3.6 (0.4)
CAPLYTA (2) 211 — * * —
CONCERTA/methylphenidate 312 340 (8.3) (7.1) (1.2)
INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA 1,895 2,110 (10.2) (9.9) (0.3)
SPRAVATO 734 496 48.1 48.4 (0.3)
Other Neuroscience 547 639 (14.4) (13.9) (0.5)
Pulmonary Hypertension 2,138 2,088 2.4 2.5 (0.1)
OPSUMIT/ OPSYNVI 1,104 1,072 3.0 3.1 (0.1)
UPTRAVI 927 894 3.7 3.8 (0.1)
Other Pulmonary Hypertension 107 123 (12.5) (12.3) (0.2)
Infectious Diseases 1,605 1,786 (10.1) (10.2) 0.1
EDURANT/rilpivirine 718 620 15.9 14.9 1.0
PREZISTA/ PREZCOBIX/ REZOLSTA/ SYMTUZA 799 856 (6.6) (6.3) (0.3)
Other Infectious Diseases (3) 88 311 (71.7) (71.3) (0.4)
Cardiovascular / Metabolism / Other 1,943 1,721 12.9 13.3 (0.4)
XARELTO 1,311 1,105 18.6 18.6 —
Other 632 616 2.7 3.9 (1.2)
Total Innovative Medicine Sales $29,075 $28,052 3.6 % 4.0 % (0.4) %

*percentage greater than 100% or not meaningful
Form 10-Q 43

Table of Contents
(1)
Includes the sales of RYBREVANT and RYBREVANT + LAZCLUZE
(2)
Acquired with the Intra-Cellular Therapies acquisition on April 2, 2025
(3)
Includes the Covid-19 Vaccine in 2024
Innovative Medicine segment sales in the fiscal second quarter of 2025 were $15.2 billion, an increase of 4.9% as compared to the same period a year ago, including an operational increase of 3.8% and a positive currency impact of 1.1%. U.S. Innovative Medicine sales increased 7.6% as compared to the same period a year ago. International Innovative Medicine sales increased by 1.0%, including an operational decline of 1.6% offset by a positive currency impact of 2.6%. In the fiscal second quarter of 2025, the net impact of acquisitions and divestitures on the worldwide Innovative Medicine segment operational sales growth was a positive 1.4%, related to CAPLYTA. In the fiscal second quarter of 2025, the negative impact of the STELARA sales decline, due to biosimilar competition, was an approximate 11.7%, 13.8% and 9.1% on worldwide, U.S. and international Innovative Medicine segment operational sales, respectively.
Major Innovative Medicine therapeutic area sales — Fiscal Second Quarter Ended
(Dollars in Millions) June 29, 2025 June 30, 2024 Total Change Operations Change Currency Change
Oncology $6,312 $5,090 24.0 % 22.3 % 1.7 %
CARVYKTI 439 186 * * *
DARZALEX 3,539 2,878 23.0 21.5 1.5
ERLEADA 908 736 23.4 21.0 2.4
IMBRUVICA 735 770 (4.5) (6.6) 2.1
RYBREVANT/ LAZCLUZE (1) 179 69 * * *
TALVEY 106 69 55.0 54.3 0.7
TECVAYLI 166 135 23.1 22.4 0.7
ZYTIGA/ abiraterone acetate 145 165 (11.6) (14.9) 3.3
Other Oncology 93 83 11.7 9.7 2.0
Immunology 3,993 4,722 (15.4) (16.0) 0.6
REMICADE 455 393 15.9 15.9 0.0
SIMPONI/ SIMPONI ARIA 690 537 28.6 27.5 1.1
STELARA 1,653 2,885 (42.7) (43.2) 0.5
TREMFYA 1,186 906 31.0 30.1 0.9
Other Immunology 8 2 * * —
Neuroscience 2,051 1,782 15.1 14.4 0.7
CAPLYTA (2) 211 — * * —
CONCERTA/ methylphenidate 164 163 0.2 (0.2) 0.4
INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA 992 1,054 (5.9) (6.3) 0.4
SPRAVATO 414 271 53.3 53.0 0.3
Other Neuroscience 270 294 (8.4) (10.7) 2.3
Pulmonary Hypertension 1,113 1,039 7.1 6.2 0.9
OPSUMIT/ OPSYNVI 582 548 6.4 5.4 1.0
UPTRAVI 476 426 11.7 11.3 0.4
Other Pulmonary Hypertension 55 67 (16.9) (19.0) 2.1
Infectious Diseases 803 965 (16.8) (19.0) 2.2
EDURANT/rilpivirine 360 297 21.6 15.5 6.1
PREZISTA/ PREZCOBIX/ REZOLSTA/ SYMTUZA 396 438 (9.4) (10.0) 0.6
Other Infectious Diseases (3) 47 233 (79.8) (79.9) 0.1
Cardiovascular / Metabolism / Other 930 892 4.2 4.0 0.2
XARELTO 621 587 5.6 5.6 —
Other 309 305 1.4 0.9 0.5
Total Innovative Medicine Sales $15,202 $14,490 4.9 % 3.8 % 1.1 %

*percentage greater than 100% or not meaningful
44

Table of Contents
(1)
Includes the sales of RYBREVANT and RYBREVANT + LAZCLUZE
(2)
Acquired with the Intra-Cellular Therapies acquisition on April 2, 2025
(3)
Includes the Covid-19 Vaccine in 2024
Oncology products achieved operational sales growth of 22.3% as compared to the same period a year ago. Strong sales of DARZALEX (daratumumab) were driven by continued share gains and market growth. Growth of ERLEADA (apalutamide) was due to continued share gains and market growth partially offset by the impact of Medicare Part D redesign. Increased sales of CARVYKTI (ciltacabtagene autoleucel) were driven by continued share gains and capacity expansion. Additionally, sales from the ongoing launches of TECVAYLI (teclistamab-cqyv), TALVEY (talquetamab-tgvs) and RYBREVANT (amivantamab)/LAZCLUZE (lazertinib) contributed to the growth. Growth was partially offset by ZYTIGA (abiraterone acetate) due to loss of exclusivity and IMBRUVICA (ibrutinib) declines due to competitive pressures and the impact of Medicare Part D redesign.
Immunology products experienced an operational decline of 16.0% as compared to the same period a year ago primarily due to the decline of STELARA (ustekinumab) sales driven by the impact of biosimilar competition and Medicare Part D redesign. The growth of TREMFYA (guselkumab) was due to share gains, market growth and launch-related inventory dynamics partially offset by the impact of Medicare Part D redesign. The increase in SIMPONI/SIMPONI ARIA sales was primarily driven by the Merck, Sharp & Dohme return of rights in Europe in the fiscal fourth quarter of 2024. The increase in REMICADE (infliximab) sales was due to favorable patient mix, market growth, and the Merck, Sharp & Dohme return of rights in Europe, partially offset by biosimilar competition.
Sales of STELARA in the United States were approximately $6.7 billion in fiscal 2024. Third parties have filed abbreviated Biologics License Applications with the FDA seeking approval to market biosimilar versions of STELARA. The Company has settled certain litigation under the Biosimilar Price Competition and Innovation Act of 2009. According to patent settlement and license agreements, the Company expects continued launches of biosimilar versions of STELARA in Europe and the United States in 2025 which will impact the Company’s sales of STELARA.
Neuroscience products, which include sales of CAPLYTA (lumateperone) acquired with the Intra-Cellular Therapies (Intra-Cellular) acquisition on April 2, 2025, achieved operational growth of 14.4% as compared to the same period a year ago. Growth of SPRAVATO (esketamine) was driven by continued increased physician and patient demand. Growth was partially offset by the sales decline of INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA primarily due to the impact of Medicare Part D redesign and unfavorable patient mix.
Pulmonary Hypertension products achieved operational sales growth of 6.2% as compared to the same period a year ago. Sales growth of OPSUMIT (macitentan)/ OPSYNVI (macitentan/tadalafil) were driven by market growth, inventory dynamics, and share gains partially offset by the impact of Medicare Part D redesign. The sales growth of UPTRAVI (selexipag) was driven by market growth and inventory dynamics partially offset by the impact of Medicare Part D redesign.
Infectious disease products experienced an operational sales decline of 19.0% as compared to the same period a year ago primarily driven by declines across the portfolio including COVID-19 vaccine revenue in Other Infectious Diseases. The decline was partially offset by growth of EDURANT/rilpivirine.
Cardiovascular / Metabolism / Other products achieved operational growth of 4.0% as compared to the same period a year ago. The growth of XARELTO (rivaroxaban) sales was primarily driven by the impact of Medicare Part D redesign and market growth partially offset by continued share declines.
The Inflation Reduction Act (IRA) contains provisions that redesign the Medicare Part D benefit in various ways, including by shifting a greater portion of costs to manufacturers within certain coverage phases and replacing the Part D coverage gap discount program with a new manufacturer discounting program.
The Company maintains a policy that no end customer will be permitted direct delivery of product to a location other than the billing location. This policy impacts contract pharmacy transactions involving non-grantee 340B covered entities for most of the Company’s drugs, subject to multiple exceptions. Both grantee and non-grantee covered entities can maintain certain contract pharmacy arrangements under policy exceptions. The Company has been and will continue to offer 340B discounts to covered entities on all of its covered outpatient drugs, and it believes its policy will improve its ability to identify inappropriate duplicate discounts and diversion prohibited by the 340B statute. The 340B Drug Pricing Program is a U.S. federal government program requiring drug manufacturers to provide significant discounts on covered outpatient drugs to covered entities.
Form 10-Q 45

Table of Contents
MedTech
The MedTech segment sales in the fiscal six months of 2025 were $16.6 billion, an increase of 5.0% as compared to the same period a year ago, with an operational increase of 5.1% and a negative currency impact of 0.1%. U.S. MedTech sales increased by 6.6%. International MedTech sales increased by 3.3%, including an operational increase of 3.6% and a negative currency impact of 0.3%. In the fiscal six months of 2025, the net impact of acquisitions and divestitures on the MedTech segment operational sales growth was a positive 2.4%, primarily related to the Shockwave acquisition.
Major MedTech franchise sales — Fiscal Six Months Ended
(Dollars in Millions) June 29, 2025 June 30, 2024 Total Change Operations Change Currency Change
Surgery $4,951 $4,904 1.0 % 1.5 % (0.5) %
Advanced 2,237 2,228 0.4 0.8 (0.4)
General 2,714 2,676 1.4 2.0 (0.6)
Orthopaedics 4,546 4,652 (2.3) (2.3) 0.0
Hips 830 839 (1.1) (1.1) 0.0
Knees 778 795 (2.0) (2.0) 0.0
Trauma 1,540 1,524 1.1 1.0 0.1
Spine, Sports & Other 1,398 1,495 (6.5) (6.7) 0.2
Cardiovascular 4,416 3,679 20.0 20.0 0.0
Electrophysiology 2,791 2,667 4.7 4.7 0.0
Abiomed 868 750 15.7 15.5 0.2
Shockwave (1) 550 77 * * —
Other Cardiovascular 207 185 11.7 11.8 (0.1)
Vision 2,648 2,543 4.1 4.2 (0.1)
Contact Lenses/Other 1,884 1,828 3.1 2.8 0.3
Surgical 764 715 6.9 7.6 (0.7)
Total MedTech Sales $16,561 $15,778 5.0 % 5.1 % (0.1) %

*Percentage greater than 100% or not meaningful
(1)
Acquired on May 31, 2024
46

Table of Contents
MedTech segment sales in the fiscal second quarter of 2025 were $8.5 billion, an increase of 7.3% as compared to the same period a year ago, which included operational growth of 6.1% and a positive currency impact of 1.2%. U.S. MedTech sales increased by 8.0%. International MedTech sales increased by 6.7%, including operational growth of 4.1% and a positive currency impact of 2.6%. In the fiscal second quarter of 2025, the net impact of acquisitions and divestitures on the MedTech segment operational sales growth was a positive 2.0%, primarily related to the Shockwave acquisition.
Major MedTech franchise sales — Fiscal Second Quarter Ended
(Dollars in Millions) June 29, 2025 June 30, 2024 Total Change Operations Change Currency Change
Surgery $2,555 $2,488 2.7 % 1.8 % 0.9 %
Advanced 1,164 1,141 2.0 1.0 1.0
General 1,391 1,346 3.3 2.5 0.8
Orthopaedics 2,305 2,312 (0.3) (1.6) 1.3
Hips 421 417 1.0 (0.2) 1.2
Knees 389 394 (1.1) (2.3) 1.2
Trauma 768 759 1.2 (0.1) 1.3
Spine, Sports & Other 727 743 (2.1) (3.7) 1.6
Cardiovascular 2,313 1,873 23.5 22.3 1.2
Electrophysiology 1,468 1,323 11.0 9.8 1.2
Abiomed 448 379 18.2 16.9 1.3
Shockwave (1) 292 77 * * —
Other Cardiovascular 104 93 10.8 9.7 1.1
Vision 1,369 1,285 6.5 4.6 1.9
Contact Lenses/Other 965 918 5.1 2.9 2.2
Surgical 403 367 9.9 8.9 1.0
Total MedTech Sales $8,541 $7,957 7.3 % 6.1 % 1.2 %

*Percentage greater than 100% or not meaningful
(1)
Acquired on May 31, 2024
The Surgery franchise achieved operational sales growth of 1.8% as compared to the prior year fiscal second quarter. The operational growth in Advanced Surgery was primarily due to the strength of the portfolio and commercial execution in Biosurgery and strategic price actions in Endocutters. The growth was partially offset by the negative impact of China volume-based procurement and competitive pressures in Energy and Endocutters. The operational growth in General Surgery was primarily driven by technology penetration and upgrades within the differentiated Wound Closure portfolio.
The Orthopaedics franchise experienced an operational sales decline of 1.6% as compared to the prior year fiscal second quarter. All platforms were impacted by revenue disruption from the previously announced Orthopaedics restructuring. The operational decline in Hips reflects the negative impact of China volume-based procurement and trade inventory dynamics partially offset by procedure growth. The operational decline in Knees was driven by competitive pressures and market headwinds, partially offset by strength of the ATTUNE portfolio and pull through related to the VELYS Robotic assisted solutions. The operational decline in Trauma was primarily driven by the lapping of the strong prior year comparator partially offset by recently launched products, procedure growth and commercial execution. The operational sales decline in Spine, Sports & Other reflects competitive pressures, price pressures in the U.S. Early Interventional segment and China volume-based procurement.
The Cardiovascular franchise, which includes sales from Shockwave Medical (Shockwave) acquired on May 31, 2024, achieved operational sales growth of 22.3% as compared to the prior year fiscal second quarter. Abiomed sales growth was driven by the continued strong adoption of Impella 5.5 and Impella CP. Electrophysiology sales growth was driven by strength in competitive mapping, new product performance, procedure growth, and lapping of prior year inventory dynamics in China partially offset by competitive pressures in Pulsed Field Ablation catheters.
The Vision franchise achieved operational sales growth of 4.6% as compared to the prior year fiscal second quarter. The Contact Lenses/Other operational growth was driven by price actions and continued strong performance in the ACUVUE OASYS 1-Day family of products (including recent launches). The Surgical operational growth was primarily driven by the continued strength of recent innovations and commercial execution.
Form 10-Q 47

Table of Contents
Analysis of consolidated earnings before provision for taxes on income
Consolidated earnings before provision for taxes on income for the fiscal six months of 2025 was $20.1 billion representing 44.1% of sales as compared to $9.5 billion in the fiscal six months of 2024, representing 21.6% of sales. The fiscal six months of 2025 includes the reversal of approximately $7.0 billion, a significant portion of the previously accrued talc reserve. The fiscal six months of 2024 includes charges for talc matters of approximately $3.0 billion.
Consolidated earnings before provision for taxes on income for the fiscal second quarter of 2025 was $6.5 billion representing 27.3% of sales as compared to $5.7 billion in the fiscal second quarter of 2024, representing 25.6% of sales.
Cost of products sold
(Dollars in billions. Percentages in chart are as a percent to total sales)
Fiscal six months Q2 2025 versus Fiscal six months Q2 2024
Cost of products sold increased as a percent to sales driven by:
•
Increased intangible asset amortization expense related to the Intra-Cellular acquisition in the Innovative Medicine business
•
Unfavorable product mix driven by the decline of STELARA sales in the Innovative Medicine business
•
Unfavorable transactional currency in the Innovative Medicine business
•
Macroeconomic factors in the MedTech business
The intangible asset amortization expense included in cost of products sold for the fiscal six months of 2025 and 2024 was $2.4 billion and $2.2 billion, respectively.
Q2 2025 versus Q2 2024
Cost of products sold increased as a percent to sales primarily driven by:
•
Unfavorable product mix driven by the decline of STELARA sales in the Innovative Medicine business
•
Increased intangible asset amortization expense related to the Intra-Cellular acquisition in the Innovative Medicine business
•
Macroeconomic factors in the MedTech business
The intangible asset amortization expense included in cost of products sold for the fiscal second quarters of 2025 and 2024 was $1.3 billion and $1.1 billion, respectively.
48

Table of Contents
Selling, marketing and administrative expenses

(Dollars in billions. Percentages in chart are as a percent to total sales)
Fiscal six months Q2 2025 versus Fiscal six months Q2 2024
Selling, Marketing and Administrative Expenses decreased as a percent to sales driven by:
•
Corporate administrative expense rationalization
•
Planned leverage and phasing of investments in the Innovative Medicine business
partially offset by
•
Increased investment in the recent acquisitions of Intra-Cellular and Shockwave
Q2 2025 versus Q2 2024
Selling, Marketing and Administrative Expenses decreased as a percent to sales primarily driven by:
•
Corporate administrative expense rationalization
partially offset by
•
Increased investment in the recent acquisitions of Intra-Cellular and Shockwave
Research and development expense
Research and development expense by segment of business was as follows:
Fiscal Second Quarter Ended Fiscal Six Months Ended
2025 2024 2025 2024
(Dollars in Millions) Amount % of Sales* Amount % of Sales* Amount % of Sales* Amount % of Sales*
Innovative Medicine $2,869 18.9 % $2,722 18.8 % $5,417 18.6 % $5,618 20.0 %
MedTech 647 7.6 718 9.0 1,324 8.0 1,364 8.6
Total research and development expense $3,516 14.8 % $3,440 15.3 % $6,741 14.8 % $6,982 16.0 %
Percent increase/(decrease) over the prior year 2.2 % (3.5 %)
*As a percent to segment sales

Fiscal six months Q2 2025 versus Fiscal six months Q2 2024
Research and Development decreased as a percent to sales driven by:
•
Planned leverage and phasing of investments in the Innovative Medicine business

Form 10-Q 49

Table of Contents
Q2 2025 versus Q2 2024
Research and Development decreased as a percent to sales driven by:
•
Portfolio rationalization and expense phasing in the MedTech business
In-process research and development (IPR&D) impairments
In the fiscal second quarter and fiscal six months of 2024, the Company recorded a charge of approximately $0.2 billion associated with the M710 (biosimilar) asset acquired with Momenta in 2020. There was also a partial impairment of this asset for $0.2 billion in the fiscal third quarter of 2023. This asset is now fully impaired.
Interest (income) expense
Interest (income) expense in the fiscal six months of 2025 was net income of $80 million as compared to net income of $334 million in the fiscal six months of 2024. Interest income in the fiscal six months of 2025 decreased as compared to the prior year driven by lower interest rates earned on cash balances. Interest expense was higher due to a higher average debt balance at higher interest rates. Interest (income) expense in the fiscal second quarter of 2025 was net expense of $48 million as compared to net income of $125 million in the fiscal second quarter of 2024. Interest income in the fiscal second quarter of 2025 decreased as compared to the prior year driven by lower interest rates earned on cash balances. Interest expense was higher due to a higher average debt balance at higher interest rates. The balance of cash, cash equivalents and current marketable securities was $18.9 billion at the end of the fiscal second quarter of 2025 as compared to $25.5 billion at the end of the fiscal second quarter of 2024. The Company’s debt position was $50.8 billion as of June 29, 2025, as compared to $41.5 billion the same period a year ago.
Other (income) expense, net*
Fiscal six months Q2 2025 versus Fiscal six months Q2 2024
Other (income) expense, net for the fiscal six months of 2025 reflected an increase in income of $10.3 billion as compared to the prior year primarily due to the following:
Fiscal Six Months
(Dollars in Billions)(Income)/Expense June 29, 2025 June 30, 2024 Change
Litigation related (1) $ (6.9) 3.1 (10.0)
Acquisition, Integration and Divestiture related 0.4 0.5 (0.1)
Changes in the fair value of securities (2) 0.1 0.4 (0.3)
Employee benefit plan related (0.3) (0.5) 0.2
Other (0.5) (0.4) (0.1)
Total Other (Income) Expense, Net $ (7.2) 3.1 (10.3)

(1)
The fiscal six months of 2025 includes the reversal of approximately $7.0 billion, a significant portion of the previously accrued talc reserve. The fiscal six months of 2024 includes charges of approximately $3.0 billion for talc matters. For additional details related to talc refer to Note 11 to the Consolidated Financial Statements.
(2)
The fiscal six months of 2024 includes the loss on the completion of the debt for equity exchange of the retained stake in Kenvue
50

Table of Contents
Q2 2025 versus Q2 2024
Other (income) expense, net for the fiscal second quarter of 2025 reflected an increase in income of $0.6 billion as compared to the prior year primarily due to the following:
Fiscal Second Quarter
(Dollars in Billions)(Income)/Expense June 29, 2025 June 30, 2024 Change
Acquisition, Integration and Divestiture related $ 0.3 0.4 (0.1)
Litigation related (1) 0.1 0.4 (0.3)
Changes in the fair value of securities (2) 0.0 0.4 (0.4)
Employee benefit plan related (0.1) (0.2) 0.1
Other (0.2) (0.3) 0.1
Total Other (Income) Expense, Net $ 0.1 0.7 (0.6)

(1)
The fiscal second quarter of 2024 includes charges for talc matters.
(2)
The fiscal second quarter of 2024 includes the loss on the completion of the debt for equity exchange of the retained stake in Kenvue.
*Other (income) expense, net is the account where the Company records gains and losses related to the sale and write-down of certain investments in equity securities held by Johnson & Johnson Innovation - JJDC, Inc. (JJDC), changes in the fair value of securities, gains and losses on divestitures, gains and losses on sale of assets, certain transactional currency gains and losses, acquisition-related costs, litigation accruals and settlements, investment (income)/loss related to employee benefit plans, as well as royalty income.
Segment income before tax
Income before tax by segment of business for the fiscal six months were as follows:
Income Before Tax Segment Sales Percent of Segment Sales
(Dollars in Millions) June 29, 2025 June 30, 2024 June 29, 2025 June 30, 2024 June 29, 2025 June 30, 2024
Innovative Medicine $10,762 $10,428 $29,075 $28,052 37.0 % 37.2 %
MedTech 2,625 2,609 16,561 15,778 15.9 16.5
Segment total 13,387 13,037 45,636 43,830 29.3 29.7
(Income) Expenses not allocated to segments (1) (6,735) 3,575
Earnings before provision for taxes on income $20,122 $9,462 $45,636 $43,830 44.1 % 21.6 %

(1)
Amounts not allocated to segments include interest (income) expense, certain litigation expenses and general corporate (income) expense. The fiscal six months of 2025 includes the reversal of approximately $7.0 billion, a significant portion of the previously accrued talc reserve. The fiscal six months of 2024 includes charges for talc matters of $3.0 billion. The fiscal six months of 2024 includes a loss of approximately $0.4 billion related to the debt to equity exchange of the Company's remaining shares of Kenvue Common Stock.
Innovative Medicine segment
The Innovative Medicine segment income before tax as a percent of sales in the fiscal six months of 2025 was 37.0% versus 37.2% for the same period a year ago. The slight decrease in the income before tax as a percent of sales for the fiscal six months of 2025 as compared to the prior year was primarily driven by the following:
•
Unfavorable Product mix and the impact of Medicare Part D redesign
•
Increased amortization and integration costs related to the Intra-Cellular acquisition
•
Unfavorable currency in Cost of products sold
partially offset by
•
An In-process research and development impairment of $0.2 billion in 2024 related to the M710 (biosimilar) asset acquired with Momenta in 2020
Form 10-Q 51

Table of Contents
•
Planned leverage and phasing of Selling, marketing and administrative expenses as well as Research & development expenses
MedTech segment
The MedTech segment income before tax as a percent of sales in the fiscal six months of 2025 was 15.9% versus 16.5% for the same period a year ago. The decrease in the income before tax as a percent of sales for the fiscal six months of 2025 was primarily driven by the following:
•
Macroeconomic factors in Cost of products sold
•
Higher litigation expense of $0.1 billion in 2025
•
A gain of $0.2 billion related to the Acclarent divestiture in 2024
partially offset by
•
Lower acquisition and integration related costs of $0.1 billion in 2025 versus $0.5 billion in 2024 related to the Shockwave acquisition
Income (loss) before tax by segment of business for the fiscal second quarters were as follows:
Income Before Tax Segment Sales Percent of Segment Sales
(Dollars in Millions) June 29, 2025 June 30, 2024 June 29, 2025 June 30, 2024 June 29, 2025 June 30, 2024
Innovative Medicine $5,552 $5,459 $15,202 $14,490 36.5 % 37.7 %
MedTech 1,204 1,089 8,541 7,957 14.1 13.7
Segment total 6,756 6,548 23,743 22,447 28.5 29.2
(Income) Expenses not allocated to segments (1) 265 800
Earnings before provision for taxes on income $6,491 $5,748 $23,743 $22,447 27.3 % 25.6 %

(1)
Amounts not allocated to segments include interest (income) expense, certain litigation expenses and general corporate (income) expense. The fiscal second quarter of 2024 includes charges for talc matters of $0.3 billion. For additional details related to talc refer to Note 11 to the Consolidated Financial Statements. The fiscal second quarter of 2024 includes a loss of approximately $0.4 billion related to the debt to equity exchange of the Company's remaining shares of Kenvue Common Stock.
Innovative Medicine segment
The Innovative Medicine segment income before tax as a percent of sales in the fiscal second quarter of 2025 was 36.5% versus 37.7% for the same period a year ago. The decrease in the income before tax as a percent of sales for the fiscal second quarter of 2025 as compared to the prior year was primarily driven by the following:
•
Unfavorable Product mix and the impact of Medicare Part D redesign
•
Increased amortization and integration costs related to the Intra-Cellular acquisition
partially offset by
•
An In-process research and development impairment of $0.2 billion in 2024 related to the M710 (biosimilar) asset acquired with Momenta in 2020
MedTech segment
The MedTech segment income before tax as a percent of sales in the fiscal second quarter of 2025 was 14.1% versus 13.7% for the same period a year ago. The increase in the income before tax as a percent of sales for the fiscal second quarter of 2025 as compared to the prior year was primarily driven by the following:
•
Shockwave acquisition and integration related costs of $0.5 billion in 2024
partially offset by
•
Macroeconomic factors in Cost of products sold
•
Higher litigation expense of $0.1 billion in 2025
•
A gain of $0.2 billion related to the Acclarent divestiture in 2024
52

Table of Contents
Restructuring
In fiscal 2025, the company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select sites across the network. Restructuring expenses of $29 million were recorded in the fiscal second quarter and fiscal six months of 2025. The estimated costs of the total program are between $0.9 billion - $1.0 billion and is expected to be completed over the next two years.
In the fiscal year 2023, the Company initiated a restructuring program of its Orthopaedics franchise within its MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The pre-tax restructuring expense was $50 million in the fiscal second quarter of 2025, of which $35 million was recorded in Restructuring and $15 million in Cost of products sold on the Consolidated Statement of Earnings primarily for costs related to market and product exits. The pre-tax restructuring expense was $105 million in the fiscal six months of 2025, of which $52 million was recorded in Restructuring and $23 million in Cost of products sold and $30 million in Other (Income)/Expense on the Consolidated Statement of Earnings primarily for costs related to asset impairments as well as market and product exits. The pre-tax restructuring expense was $52 million in the fiscal second quarter of 2024, of which $50 million was recorded in Restructuring and $2 million was recorded in Cost of products sold on the Consolidated Statement of Earnings. The pre-tax restructuring expense was $79 million in the fiscal six months of 2024, of which $70 million was recorded in Restructuring and $9 million was recorded in Cost of products sold on the Consolidated Statement of Earnings. Total project costs of approximately $0.6 billion have been recorded since the restructuring was announced.
In the fiscal year 2023, the Company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. The pre-tax restructuring charge of approximately $0.1 billion in the fiscal six months of 2024 included the termination of partnered and non-partnered program costs and asset impairments. The program was completed in the fiscal fourth quarter of 2024.
For further details related to the restructuring refer to Note 12 to the Consolidated Financial Statements.
Provision for taxes on income
The worldwide effective income tax rate for the fiscal six months was 17.8% in 2025 and 16.1% in 2024.
On December 15, 2022, the European Union (EU) Member States formally adopted the EU’s Pillar Two Directive, which generally provides for a minimum effective tax rate of 15%, as established by the Organization for Economic Co-operation and Development (OECD) Pillar Two Framework that was supported by over 130 countries worldwide. Several EU and non-EU countries have enacted Pillar Two legislation with an initial effective date of January 1, 2024, with other aspects of the law effective in 2025 or later. While countries continue to enact new provisions or issue new regulations this could have an impact to the Company’s effective tax rate. The Company will continue to monitor further developments to determine any potential impact in the countries in which we operate, such as the recently announced understanding between the U.S. and the G7 of a side-by-side system that would fully exclude U.S. parented groups from certain provisions of the Pillar Two Framework.
For further details related to the fiscal 2025 provision for taxes refer to Note 5 to the Consolidated Financial Statements.
Liquidity and capital resources
Acquisitions
(net of cash acquired)
Proceeds from the disposal of assets/businesses, net
Form 10-Q 53

Table of Contents
Dividends to shareholders
Cash flows
Cash and cash equivalents were $18.6 billion at the end of the fiscal second quarter of 2025 as compared with $24.1 billion at the end of fiscal year 2024. The primary sources and uses of cash that contributed to the $5.5 billion decrease were:
(Dollars In Billions)
24.1 Q4 2024 Cash and cash equivalents balance
8.1 net cash generated from operating activities
(18.6) net cash used by investing activities
4.8 net cash from financing activities
0.2 effect of exchange rate changes on cash and cash equivalents
$ 18.6 Q2 2025 Cash and cash equivalents

In addition, the Company had $0.3 billion in marketable securities at the end of the fiscal second quarter of 2025 and $0.4 billion at the end of fiscal year 2024.
Cash flow from operations of $8.1 billion was the result of:
(Dollars In Billions)
$ 16.5 Net earnings
7.5 non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation, deferred tax provision, charge for in-process research and development assets and asset write-downs partially offset by the net gain on sale of assets/businesses
(2.9) an increase in accounts receivable and inventories
(0.9) a decrease in accounts payable and accrued liabilities
(6.2) an increase in other current and non-current assets
(5.9) a decrease in other current and non-current liabilities
$ 8.1 Net cash flows from operations

Cash flow used by investing activities of $18.6 billion was primarily from:
54

Table of Contents
(Dollars In Billions)
$ (1.8) additions to property, plant and equipment
0.3 proceeds from the disposal of assets/businesses, net
(14.5) acquisitions, net of cash acquired
(0.4) acquired in-process research and development assets/related milestones
0.5 net sales of investments
(2.7) credit support agreements activity, net
0.0 Other and rounding
$ (18.6) Net cash used by investing activities

Cash flow from financing activities of $4.8 billion was primarily from:
(Dollars In Billions)
$ (6.1) dividends to shareholders
(2.1) repurchase of common stock
12.7 net proceeds from short and long term debt
0.6 proceeds from stock options exercised/employee withholding tax on stock awards, net
(0.3) credit support agreements activity, net
0.0 Other and rounding
$ 4.8 Net cash from financing activities

The following table summarizes cash taxes paid net of refunds:
(Dollars in Millions) June 29, 2025 December 29, 2024
Total U.S. (1) 3,710 4,156
Total Foreign 1,331 2,558
Total cash taxes paid net of refunds 5,041 6,714

(1)
Represents Federal and State taxes and includes TCJA foreign undistributed earnings payments of $2.5 billion in 2025 and $2.0 billion in 2024
The Company has access to substantial sources of funds at numerous banks worldwide and has the ability to issue up to $20 billion in Commercial Paper. Furthermore, in June 2025, the Company secured a new 364-day Credit Facility of $10 billion (expiration on June 24, 2026) which may be used for general corporate purposes including to support our commercial paper borrowings. Interest charged on borrowings under the credit line agreement is based on either Secured Overnight Financing Rate (SOFR) Reference Rate or other applicable market rate as allowed plus applicable margins. Commitment fees under the agreement are not material.
As of June 29, 2025, the Company had cash, cash equivalents and marketable securities of approximately $18.9 billion and had approximately $50.8 billion of notes payable and long-term debt for a net debt position of $31.9 billion as compared to the prior year fiscal second quarter net debt position of $16.0 billion. In the fiscal first quarter of 2025, the Company issued senior unsecured notes for approximately $9.2 billion. For additional details on borrowings, see Note 4 to the Consolidated Financial Statements. The net proceeds from this offering were used to fund the Intra-Cellular Therapies, Inc. acquisition for approximately
Form 10-Q 55

Table of Contents
$14.5 billion which closed on April 2, 2025, and for general corporate purposes. The Company anticipates that operating cash flows, the ability to raise funds from external sources, borrowing capacity from existing committed credit facilities and access to the commercial paper markets will continue to provide sufficient resources to fund operating needs, including the Company’s remaining balance of approximately $4.0 billion related to talc matters, $3.0 billion related to the current portion of Corporate bonds due and the remaining approximately $1.1 billion to settle opioid litigation (See Note 11 to the Consolidated Financial Statements for additional details). In addition, the Company monitors the global capital markets on an ongoing basis and from time to time may raise capital when market conditions are favorable.
Dividends
On April 15, 2025, the Board of Directors declared a regular cash dividend of $1.30 per share, payable on June 10, 2025, to shareholders of record as of May 27, 2025.
On July 16, 2025, the Board of Directors declared a regular cash dividend of $1.30 per share, payable on September 9, 2025, to shareholders of record as of August 26, 2025. The Company expects to continue the practice of paying regular quarterly cash dividends.
Other information
New accounting pronouncements
Refer to Note 1 to the Consolidated Financial Statements for new accounting pronouncements.
Economic and market factors
In July 2023, Janssen Pharmaceuticals, Inc. (Janssen) filed litigation against the U.S. Department of Health and Human Services as well as the Centers for Medicare and Medicaid Services challenging the constitutionality of the IRA's Medicare Drug Price Negotiation Program. The litigation requests a declaration that the IRA violates Janssen’s rights under the First Amendment and the Fifth Amendment to the Constitution and therefore that Janssen is not subject to the IRA’s mandatory pricing scheme. The impact of the IRA on our business and the broader pharmaceutical industry remains uncertain, as litigation filed by Janssen and other pharmaceutical companies remains ongoing and while CMS has publicly announced the maximum fair price for each of the selected drugs, implementation of the program is still in progress. In April 2024, Janssen appealed the district court’s denial of its summary judgment motion to the Third Circuit.
Russia-Ukraine war
Although the long-term implications of Russia’s invasion of Ukraine are difficult to predict at this time, the financial impact of the conflict in the fiscal second quarter of 2025, including accounts receivable or inventory reserves, was not material. As of the fiscal six months ending June 29, 2025, and the fiscal year ending December 29, 2024, the business of the Company’s Russian subsidiaries represented less than 1% of the Company’s consolidated assets and represented approximately 1% of revenues. The Company does not maintain Ukrainian subsidiaries.
In March of 2022, the Company took steps to suspend all advertising, enrollment in clinical trials, and any additional investment in Russia. The Company continues to supply products relied upon by patients for healthcare purposes.
Conflict in the Middle East
Although the long-term implications of the conflict in the Middle East are difficult to predict at this time, the financial impact of the conflict in the fiscal second quarter of 2025, including accounts receivable or inventory reserves, was not material. As of the fiscal six months ending June 29, 2025, and the fiscal year ending December 29, 2024, the business of the Company’s Israel subsidiaries represented less than 1% of both Company’s consolidated assets and revenues.
Other Macroeconomic Considerations
The Company operates in certain countries where the economic conditions continue to present significant challenges. The Company continues to monitor these situations and take appropriate actions. Inflation rates and currency exchange rates continue to have an effect on worldwide economies and, consequently, on the way the Company operates. The Company has accounted for operations in Venezuela, Argentina, Turkey and Egypt (beginning in the fiscal fourth quarter of 2024) as highly inflationary, as the
56

Table of Contents
prior three-year cumulative inflation rate surpassed 100%. In the face of increasing costs, the Company strives to maintain its profit margins through cost reduction programs, productivity improvements and periodic price increases.
Governments around the world consider various proposals to make changes to tax laws, which may include increasing or decreasing existing statutory tax rates. In connection with various government initiatives, companies are required to disclose more information to tax authorities on operations around the world, which may lead to greater audit scrutiny of profits earned in other countries. A change in statutory tax rate in any country would result in the revaluation of the Company’s deferred tax assets and liabilities related to that particular jurisdiction in the period in which the new tax law is enacted. This change would result in an expense or benefit recorded to the Company’s Consolidated Statement of Earnings. The Company closely monitors these proposals as they arise in the countries where it operates. Changes to the statutory tax rate may occur at any time, and any related expense or benefit recorded may be material to the fiscal quarter and year in which the law change is enacted.
The Company may be further impacted by the imposition of tariffs, trade protection measures or other policies adopted by any jurisdiction that favor domestic companies and technologies over foreign competitors.
The Company faces various worldwide health care changes that may continue to result in pricing pressures that include health care cost containment and government legislation relating to sales, promotions and reimbursement of health care products.
Changes in the behavior and spending patterns of purchasers of healthcare products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and foregoing healthcare insurance coverage, may continue to impact the Company’s businesses.
The Company faces regular intellectual property challenges from third parties, including generic and biosimilar manufacturers, seeking to manufacture and market generic and biosimilar versions of key pharmaceutical products prior to the expiration of the applicable patents. These challengers file Abbreviated New Drug Applications or abbreviated Biologics License Applications with the FDA or otherwise challenged the coverage and/or validity of the Company’s patents. In the event the Company is not successful in defending the patent claims challenged in the resulting lawsuits, generic or biosimilar versions of the products at issue may be introduced to the market, resulting in the potential for substantial market share and revenue losses for those products, and which may result in a non-cash impairment charge in any associated intangible asset. There is also risk that one or more competitors could launch a generic or biosimilar version of the product at issue following regulatory approval even though one or more valid patents are in place.
Item 3 — Quantitative and qualitative disclosures about market risk
There has been no material change in the Company’s assessment of its sensitivity to market risk since its presentation set forth in Item 7A, “Quantitative and Qualitative Disclosures About Market Risk,” in its Annual Report on Form 10-K for the fiscal year ended December 29, 2024.
Item 4 — Controls and procedures
Disclosure controls and procedures. At the end of the period covered by this report, the Company evaluated the effectiveness of the design and operation of its disclosure controls and procedures. The Company’s disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Joaquin Duato, Chief Executive Officer; Chairman, Executive Committee and Joseph J. Wolk, Executive Vice President, Chief Financial Officer, reviewed and participated in this evaluation. Based on this evaluation, Messrs. Duato and Wolk concluded that, as of the end of the period covered by this report, the Company’s disclosure controls and procedures were effective.
Internal control. During the period covered by this report, there were no changes in the Company’s internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting. The Company continues to monitor and assess the effectiveness of the design and operation of its disclosure controls and procedures.
Form 10-Q 57

Table of Contents
The Company is implementing a multi-year, enterprise-wide initiative to integrate, simplify and standardize processes and systems for the human resources, information technology, procurement, supply chain and finance functions. These are enhancements to support the growth of the Company’s financial shared service capabilities and standardize financial systems. This initiative is not in response to any identified deficiency or weakness in the Company’s internal control over financial reporting. In response to this initiative, the Company has and will continue to align and streamline the design and operation of its financial control environment.
58

Table of Contents
Part II — Other information
Item 1 — Legal proceedings
The information called for by this item is incorporated herein by reference to Note 11 included in Part I, Item 1, Financial Statements (unaudited) — Notes to Consolidated Financial Statements.
Item 2 — Unregistered sales of equity securities and use of proceeds
(c) Purchases of Equity Securities by the Issuer and Affiliated Purchasers.
The following table provides information with respect to Common Stock purchases by the Company during the fiscal second quarter of 2025. Common stock purchases on the open market are made as part of a systematic plan to meet the needs of the Company's compensation programs. The repurchases below also include the stock-for-stock option exercises that settled in the fiscal second quarter.
Fiscal Month Period Total Number of Shares Purchased (1) Avg. Price Per Share Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs
March 31, 2025 through April 27, 2025 — — — —
April 28, 2025 through May 25, 2025 — — — —
May 26, 2025 through June 29, 2025 — — — —
Total — — — —

(1)
During the fiscal second quarter of 2025, the Company did not repurchase any shares of Johnson & Johnson Common Stock in open-market transactions.
Form 10-Q 59

Table of Contents
Item 5 — Other information
Securities trading plans of Directors and Executive Officers
. During the fiscal second quarter of 2025, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) informed us of the
adoption
or
termination
of a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” each as defined in Item 408 of Regulation S-K.
Item 6 — Exhibits
Exhibit 31.1
Certification of Chief Executive Officer under Rule 13a-14(a) of the Securities Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 — Filed with this document.
Exhibit 31.2
Certification of Chief Financial Officer under Rule 13a-14(a) of the Securities Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 — Filed with this document.
Exhibit 32.1
Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 — Furnished with this document.
Exhibit 32.2
Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 — Furnished with this document.
Exhibit 101:
EX-101.INS Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
EX-101.SCH Inline XBRL Taxonomy Extension Schema
EX-101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase
EX-101.LAB Inline XBRL Taxonomy Extension Label Linkbase
EX-101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase
EX-101.DEF Inline XBRL Taxonomy Extension Definition Document
Exhibit 104: Cover Page Interactive Data File––the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

60

Table of Contents
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: July 24, 2025

Date: July 24, 2025

JOHNSON & JOHNSON
(Registrant)

By /s/ J. J. Wolk
J. J. Wolk , Executive Vice President, Chief Financial Officer (Principal Financial Officer)

By /s/ R. J. Decker Jr.
R. J. Decker Jr. , Controller (Principal Accounting Officer)

Form 10-Q 61